var title_f10_62_11232="HIE pathophysiology";
var content_f10_62_11232=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 620px\">",
"   <div class=\"ttl\">",
"    Pathophysiology of  hypoxic-ischemic encephalopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 600px; height: 402px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The downward pointing blue line represents the cascade of events that occurs with oxidative stress, and the downward pointing black line depicts events associated with energy failure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Sidhartha Tan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_62_11232=[""].join("\n");
var outline_f10_62_11232=null;
var title_f10_62_11233="Trimetazidine: International drug information";
var content_f10_62_11233=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Trimetazidine: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4369842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Centrophene (FR);",
"     </li>",
"     <li>",
"      Flavedon (IN);",
"     </li>",
"     <li>",
"      Idaptan (ES);",
"     </li>",
"     <li>",
"      Imovexil (GR);",
"     </li>",
"     <li>",
"      Liomagen (GR);",
"     </li>",
"     <li>",
"      Matenol (TH);",
"     </li>",
"     <li>",
"      Metacard (IN);",
"     </li>",
"     <li>",
"      Vastarel (AR, BR, DK, FR, GR, HK, IE, IT, MY, PT, SG, TH);",
"     </li>",
"     <li>",
"      Vastinol (TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F2523455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Trimetazidine Dichorhydrate;",
"     </li>",
"     <li>",
"      Trimetazidine Dihydrochloride;",
"     </li>",
"     <li>",
"      Trimetazidine Hydrochloride",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2676359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Cardiovascular Agent, Other",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F2523456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Long-term treatment of angina pectoris",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F2523458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Angina: 20 mg 3 times/day with meals",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2523459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Tablet, as dihydrochloride: 20 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10486 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-996A9847C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_62_11233=[""].join("\n");
var outline_f10_62_11233=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4369842\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2523455\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2676359\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2523456\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2523458\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821191\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2523459\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10486\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10486|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_62_11234="Carotid artery angiogram";
var content_f10_62_11234=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F63788&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F63788&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal internal carotid artery angiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 394px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An angiogram showing the normal radiographic appearance of the internal carotid artery and its branches. The internal carotid enters the skull at the carotid foramen, passes anteromedially, and then rises vertically (C6) to pass forward opposite the sella turcica (C4). The artery then passes upward within the dura (C3) and emerges below and medial to the anterior clinoid (C2), giving rise to the ophthalmic artery. The carotid then bifurcates (C1) to form the anterior and middle cerebral arteries. The anterior cerebral artery is directed anteromedially (A1) till it reaches the midline, where it turns upward (A2) to be joined by the anterior communicating artery. The middle cerebral artery extends laterally (M1).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Leonard H Sigal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_62_11234=[""].join("\n");
var outline_f10_62_11234=null;
var title_f10_62_11235="Hepatic hemangioma Gross";
var content_f10_62_11235=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F53994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F53994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hepatic hemangioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gross specimen of a hepatic hemangioma. The cut surface demonstrates a brown to red appearance with areas of focal hemorrhage and fibrosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Imad Nasser, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_62_11235=[""].join("\n");
var outline_f10_62_11235=null;
var title_f10_62_11236="Patient information: Breast reconstruction after mastectomy (The Basics)";
var content_f10_62_11236=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16241\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/41/22160\">",
"         Reconstruction with an implant",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/37/25173\">",
"          Reconstruction with pedicled (attached) TRAM flap",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/27/438\">",
"           Reconstruction with free TRAM flap",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/47/33523\">",
"            Reconstruction with Lat flap",
"           </a>",
"           <li>",
"            <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/58/41892\">",
"             Reconstruction with a DIEP flap",
"            </a>",
"           </li>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?2/19/2357\">",
"         Patient information: Breast cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/59/19379\">",
"         Patient information: Breast cancer screening (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/63/10227\">",
"         Patient information: Cancer screening (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?8/8/8321\">",
"         Patient information: Choosing treatment for early-stage breast cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/62/6115\">",
"         Patient information: Common breast problems (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/53/25426\">",
"         Patient information: Adjuvant medical therapy for HER2-positive breast cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/56/12167\">",
"         Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/40/36481\">",
"         Patient information: Breast cancer screening (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/52/26437\">",
"         Patient information: Early stage breast cancer treatment in postmenopausal women (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/2/39970\">",
"         Patient information: Early stage breast cancer treatment in premenopausal women (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/44/27335\">",
"         Patient information: Surgical procedures for breast cancer &mdash; Mastectomy and breast conserving therapy (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Breast reconstruction after mastectomy (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/breast-reconstruction-after-mastectomy-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H14058998\">",
"      <span class=\"h1\">",
"       What is breast reconstruction?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Breast reconstruction is surgery to rebuild a breast that was removed to treat or prevent cancer. Reconstruction can be done using man-made materials, called implants, or using tissue taken from other parts of your body, called &ldquo;flaps.&rdquo;",
"     </p>",
"     <p>",
"      If you are planning to have surgery to remove a breast, called a mastectomy, talk to your surgeon about reconstruction before you have the mastectomy. Your mastectomy might need to be done in a certain way for you to be able to have the type of reconstruction you want.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14059005\">",
"      <span class=\"h1\">",
"       Do I need breast reconstruction after mastectomy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No, you do not need it. The decision to have reconstruction is totally up to you. Some women feel better about themselves or feel like they look more normal if they have reconstruction after mastectomy. Other women do not mind having only 1 breast. The important thing is that you have a choice about what to do.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14059012\">",
"      <span class=\"h1\">",
"       What if I decide not to have reconstruction?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you decide not to have reconstruction, the side of your chest that had surgery will be flat and have a scar on it. If you want, you can wear a special bra with a pocket for a soft plastic breast. That way you'll look more even, and your clothes will probably fit better.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14059019\">",
"      <span class=\"h1\">",
"       When can I have my breast reconstructed?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Breast reconstruction can be done at the time of mastectomy or later. The timing for you will depend on the stage of your cancer and what other treatments you need.",
"     </p>",
"     <p>",
"      Women with early-stage cancer or who are having mastectomies to prevent cancer can have the reconstruction at the same time as their mastectomy. This is called &ldquo;immediate reconstruction.&rdquo; Women who are having immediate reconstruction can have a &ldquo;skin-sparing&rdquo; mastectomy, which removes the breast tissue, but leaves as much of the healthy skin as possible. The skin that is left can then be used like a pocket to hold the tissue that will make up the new breast.",
"     </p>",
"     <p>",
"      Women with later-stage cancer sometimes need to have radiation after mastectomy. (Radiation is a treatment that kills cancer cells.) These women need to delay reconstruction until the radiation treatment is finished. This is called &ldquo;delayed reconstruction.&rdquo; The delay is needed because the reconstructed breast could keep the radiation from reaching the right areas. Plus, radiation could damage the reconstructed breast.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14059026\">",
"      <span class=\"h1\">",
"       What are the different ways that surgeons can reconstruct a breast?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The 2 main ways are with implants or with flaps. Plus, there are several kinds of flaps, each named for the muscles they are made of. The best reconstruction approach for you will depend on:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        How big your breasts are to begin with",
"       </li>",
"       <li>",
"        How much extra body fat you have and where",
"       </li>",
"       <li>",
"        Whether you smoke, are overweight, or have health problems, such as diabetes, or heart or lung disease",
"       </li>",
"       <li>",
"        Whether you have had surgery before and on what part of your body, because scars might affect which tissue can be used",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14059033\">",
"      <span class=\"h1\">",
"       How does reconstruction with an implant work?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A breast implant is basically a breast-shaped container that is filled with salt-water (called &ldquo;saline&rdquo;) or something that feels like Jell-O (called &ldquo;silicone&rdquo;). The implant is inserted under a layer of muscle in the chest.",
"     </p>",
"     <p>",
"      Getting an implant usually involves 2 steps. First, the surgeon inserts a device called an &ldquo;expander.&rdquo; This device stretches the skin and muscle in the chest, so that they can hold the implant. Doctors gradually add more and more fluid to the expander until the skin and muscle are stretched enough for the implant. Then, the surgeon does another surgery to insert the implant (",
"      <a class=\"graphic graphic_figure graphicRef69825 \" href=\"UTD.htm?21/41/22160\">",
"       figure 1",
"      </a>",
"      ). Implants are best for women with smaller breasts that don&rsquo;t droop.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14059040\">",
"      <span class=\"h1\">",
"       How does reconstruction with a flap work?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on which type of flap is used. The most commonly used flaps are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         TRAM flaps",
"        </strong>",
"        &mdash; A TRAM flap is taken from the belly and is made up of skin, fat, and muscle. When the muscle in the flap stays attached to the blood vessels that supply it, it is called a &ldquo;pedicled TRAM flap&rdquo; (",
"        <a class=\"graphic graphic_figure graphicRef79289 \" href=\"UTD.htm?24/37/25173\">",
"         figure 2",
"        </a>",
"        ). This type of flap is tunneled under the skin from the tummy to the new breast pocket.",
"        <br/>",
"        <br/>",
"        When the flap is completely disconnected from the belly and its blood vessels, it is called a &ldquo;free TRAM flap&rdquo; (",
"        <a class=\"graphic graphic_figure graphicRef58550 \" href=\"UTD.htm?0/27/438\">",
"         figure 3",
"        </a>",
"        ). This type of flap is attached to a new set of blood vessels in the chest. It doesn&rsquo;t stay connected, so it does not have to be tunneled to its new location.",
"        <br/>",
"        <br/>",
"        Both kinds of TRAM flaps can be done only in women who have enough belly fat to make a flap. After surgery, the belly looks flatter, like it does after a &ldquo;tummy tuck.&rdquo; Women who have this type of flap have a scar along their bikini line from hip to hip.",
"       </li>",
"       <li>",
"        <strong>",
"         Lat flap",
"        </strong>",
"        &mdash; A Lat flap is taken from the back and is made up of skin, fat, and muscle. The flap stays attached to its own blood supply and is tunneled under the skin from the back to the chest. Women who have this kind of flap have a scar on their back beneath the bra line. They also often also get an implant, because there is not enough fat on the back to make a new breast (",
"        <a class=\"graphic graphic_figure graphicRef72302 \" href=\"UTD.htm?32/47/33523\">",
"         figure 4",
"        </a>",
"        ). &nbsp;",
"       </li>",
"       <li>",
"        <strong>",
"         DIEP flap",
"        </strong>",
"        &mdash; A DIEP flap is taken from the belly, but it is different from a TRAM flap because it is made up of skin and fat but NOT muscle (",
"        <a class=\"graphic graphic_figure graphicRef82619 \" href=\"UTD.htm?40/58/41892\">",
"         figure 5",
"        </a>",
"        ). Connecting these flaps to a good blood supply is harder than it is for other flaps. That means the surgery can be more complicated and take longer.",
"       </li>",
"       <li>",
"        <strong>",
"         Flaps taken from other places",
"        </strong>",
"        &mdash; Women who do not have enough belly fat to make good TRAM or DIEP flaps can have flaps taken from other parts of their body. For instance, doctors sometimes take flaps from the rear end or inner thigh. &nbsp;",
"        <strong>",
"        </strong>",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14059047\">",
"      <span class=\"h1\">",
"       Will my nipple be reconstructed?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want it to be, yes. Nipple reconstruction is usually done a few months after the breast construction is done. To make a new nipple, the surgeon can rearrange the tissue that is already there or use tissue from another part of the body. Surgeons also sometimes tattoo the nipple and the area around the nipple to make it the right color.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14059054\">",
"      <span class=\"h1\">",
"       Will my new breast match my other breast?",
"      </span>",
"      &nbsp;&mdash;&nbsp;As much as possible, yes. But the new breast will never be like the one you had before or like the other breast. Plus, you won&rsquo;t have normal feeling (sensation) in the new breast. Your surgeon might need to operate on your healthy breast to make the 2 breasts look as similar as possible.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14059061\">",
"      <span class=\"h1\">",
"       Can I choose which kind of reconstruction to have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes and no. Only some of the reconstruction types will be appropriate for you. But if you think you would rather have 1 type of reconstruction over another, ask your surgeon if that approach would work for you. He or she can tell you if your choice makes sense, and if not, why not.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14059219\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/19/2357?source=see_link\">",
"       Patient information: Breast cancer (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/8/8321?source=see_link\">",
"       Patient information: Choosing treatment for early-stage breast cancer (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/59/19379?source=see_link\">",
"       Patient information: Breast cancer screening (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/62/6115?source=see_link\">",
"       Patient information: Common breast problems (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=see_link\">",
"       Patient information: Cancer screening (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=see_link\">",
"       Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/44/27335?source=see_link\">",
"       Patient information: Surgical procedures for breast cancer &mdash; Mastectomy and breast conserving therapy (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/40/36481?source=see_link\">",
"       Patient information: Breast cancer screening (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/52/26437?source=see_link\">",
"       Patient information: Early stage breast cancer treatment in postmenopausal women (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/2/39970?source=see_link\">",
"       Patient information: Early stage breast cancer treatment in premenopausal women (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/53/25426?source=see_link\">",
"       Patient information: Adjuvant medical therapy for HER2-positive breast cancer (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?10/62/11236?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16241 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-2.133.93.82-D9A3241E76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_62_11236=[""].join("\n");
var outline_f10_62_11236=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14058998\">",
"      What is breast reconstruction?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14059005\">",
"      Do I need breast reconstruction after mastectomy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14059012\">",
"      What if I decide not to have reconstruction?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14059019\">",
"      When can I have my breast reconstructed?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14059026\">",
"      What are the different ways that surgeons can reconstruct a breast?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14059033\">",
"      How does reconstruction with an implant work?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14059040\">",
"      How does reconstruction with a flap work?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14059047\">",
"      Will my nipple be reconstructed?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14059054\">",
"      Will my new breast match my other breast?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14059061\">",
"      Can I choose which kind of reconstruction to have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14059219\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16241\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/41/22160\">",
"      Reconstruction with an implant",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/37/25173\">",
"       Reconstruction with pedicled (attached) TRAM flap",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/27/438\">",
"        Reconstruction with free TRAM flap",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/47/33523\">",
"         Reconstruction with Lat flap",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/58/41892\">",
"          Reconstruction with a DIEP flap",
"         </a>",
"        </li>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/53/25426?source=related_link\">",
"      Patient information: Adjuvant medical therapy for HER2-positive breast cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/19/2357?source=related_link\">",
"      Patient information: Breast cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=related_link\">",
"      Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/40/36481?source=related_link\">",
"      Patient information: Breast cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/59/19379?source=related_link\">",
"      Patient information: Breast cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=related_link\">",
"      Patient information: Cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/8/8321?source=related_link\">",
"      Patient information: Choosing treatment for early-stage breast cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/62/6115?source=related_link\">",
"      Patient information: Common breast problems (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/52/26437?source=related_link\">",
"      Patient information: Early stage breast cancer treatment in postmenopausal women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/2/39970?source=related_link\">",
"      Patient information: Early stage breast cancer treatment in premenopausal women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/44/27335?source=related_link\">",
"      Patient information: Surgical procedures for breast cancer &mdash; Mastectomy and breast conserving therapy (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_62_11237="Anencephaly";
var content_f10_62_11237=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anencephaly",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/62/11237/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/62/11237/contributors\">",
"     Tadanori Tomita, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/62/11237/contributors\">",
"     Hideki Ogiwara, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/62/11237/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/62/11237/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/62/11237/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/62/11237/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/62/11237/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/62/11237/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H13323850\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anencephaly is characterized by an open defect in the calvaria and skin, such that the cranial neural tube is exposed. It is a severe defect and is not compatible with survival. Infants that are alive at birth generally die within hours but occasionally survive for a few days or weeks. The clinical features, diagnosis, and management of anencephaly are discussed in this topic review.",
"   </p>",
"   <p>",
"    Anencephaly is one of the three major neural tube defects (NTDs). The others are encephalocele and myelomeningocele, which are discussed in separate topic reviews:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Encephalocele, which is a herniation of the brain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      meninges through a defect in the skull (cranium bifidum) that is &ldquo;closed&rdquo; or covered with skin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3991?source=see_link\">",
"       \"Primary (congenital) encephalocele\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Myelomeningocele, which is characterized by a cleft in the vertebral column, with a corresponding defect in the skin so that the meninges and spinal cord are exposed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33767?source=see_link\">",
"       \"Pathophysiology and clinical manifestations of myelomeningocele (spina bifida)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26344?source=see_link\">",
"       \"Overview of the management of myelomeningocele (spina bifida)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13324094\">",
"    <span class=\"h1\">",
"     EMBRYOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The central nervous system (CNS) appears as a plate of thickened ectoderm called the neural plate at the beginning of the third week of embryonic life. The lateral edges of the neural plate become elevated to form the neural folds and fuse to form the neural tube; the fusion begins in the cervical region and proceeds in both the rostral and caudal directions (",
"    <a class=\"graphic graphic_figure graphicRef81711 \" href=\"UTD.htm?20/24/20879\">",
"     figure 1",
"    </a>",
"    ). The rostral neuropore closes on the 25th day after conception, and the caudal neuropore closes two days later [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11237/abstract/1\">",
"     1",
"    </a>",
"    ]. Neural tube defects (NTDs) result from failure of the neural tube closure between 25 and 27 days after conception. The embryology of the neural tube is discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20921?source=see_link&amp;anchor=H19221419#H19221419\">",
"     \"Pathogenesis and types of occult spinal dysraphism\", section on 'Normal cord development in humans'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anencephaly is a severe defect of development of the neuraxis, in which the developing forebrain and variable amounts of the brainstem are exposed in utero and fail to develop or are destroyed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11237/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Anencephaly results from failure of the rostral neuropore to close around postovulatory day 25 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11237/abstract/4\">",
"     4",
"    </a>",
"    ], whereas spina bifida results from failure of the caudal neuropore to close around postovulatory day 27.",
"   </p>",
"   <p>",
"    The craniofacial abnormalities in anencephaly are caused by abnormal neural induction from prosencephalic and mesencephalic neural crest tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11237/abstract/5\">",
"     5",
"    </a>",
"    ]. This mechanism is also seen in other anomalies of craniofacial development such as holoprosencephaly. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Craniorachischisis totalis is a related neural tube defect, in which anencephaly is accompanied by a contiguous open defect of the spine (spina bifida totalis). It is an extreme example of defective closure of the neural tube during early embryogenesis, around 20 to 22 days gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11237/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13324782\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to data from birth certificates reported to the National Center for Health Statistics, the prevalence of anencephaly in the United States in 2001 was 9.40 per 100,000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11237/abstract/8\">",
"     8",
"    </a>",
"    ]. During 1999 to 2004, 2116 cases of anencephaly were reported in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11237/abstract/9\">",
"     9",
"    </a>",
"    ]. Hispanic infants had the highest prevalence. The malformation is more common in girls than boys, in whites than blacks, and in mothers at the younger and older extremes of age [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11237/abstract/10\">",
"     10",
"    </a>",
"    ]. The rate of anencephaly in live births underestimates the actual rate of occurrence because of unknown numbers of spontaneous abortion or pregnancy termination of affected fetuses.",
"   </p>",
"   <p>",
"    The birth prevalence of anencephaly decreased 20 percent between the 1999 to 2000 period and the 2003 to 2004 survey periods [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11237/abstract/9\">",
"     9",
"    </a>",
"    ]. This decline is thought to be due to mandatory fortification of foods with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/31/22005?source=see_link\">",
"     folic acid",
"    </a>",
"    , which began in January 1998.",
"   </p>",
"   <p>",
"    There is considerable variation in the rates of anencephaly and other NTDs worldwide, with particularly high prevalence in Ireland and the British Islands as compared with continental Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11237/abstract/11\">",
"     11",
"    </a>",
"    ]. Rates in Asia and Africa tend to be lower, although there are pockets of higher prevalence in the northern provinces of China and in India, which are not easily explained by geographic or ethnic gradients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11237/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13324789\">",
"    <span class=\"h1\">",
"     RECURRENCE RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of recurrence for NTDs (spina bifida or anencephaly) is approximately 2 to 4 percent when there is one affected sibling [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11237/abstract/13-17\">",
"     13-17",
"    </a>",
"    ]. With two affected siblings, the risk is approximately 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11237/abstract/18\">",
"     18",
"    </a>",
"    ]. The risk of recurrence appears to be higher in countries such as Ireland where the prevalence of NTDs is high [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11237/abstract/19\">",
"     19",
"    </a>",
"    ]. This familial clustering is due to genetic factors, environmental influences, or a combination of the two [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11237/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The environmental influences that contribute to anencephaly risk are similar to those of other NTDs. (See",
"    <a class=\"local\" href=\"#H13324831\">",
"     'Prevention'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13324796\">",
"    <span class=\"h1\">",
"     PRENATAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal diagnosis is accomplished by maternal screening of serum alpha-fetoprotein (AFP) levels and ultrasonography. Prenatal detection usually is followed by termination of the pregnancy.",
"   </p>",
"   <p>",
"    The sonographic diagnosis of anencephaly is based upon the absence of brain and calvaria superior to the orbits on coronal views of the fetal head. The sonographic diagnosis of this condition is highly accurate and should be obvious on any routine second- or third-trimester ultrasound examination. Another sonographic feature is polyhydramnios, which develops in up to 50 percent of the cases during the second and third trimester due to decreased fetal swallowing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35560?source=see_link&amp;anchor=H3#H3\">",
"     \"Ultrasound diagnosis of neural tube defects\", section on 'Anencephaly'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13324803\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the most common type of anencephaly, the forebrain and variable amounts of upper brainstem are involved [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11237/abstract/10\">",
"     10",
"    </a>",
"    ]. Exposure in utero results in destruction of neural tissue, which appears as a hemorrhagic, fibrotic, nonfunctioning mass (",
"    <a class=\"graphic graphic_picture graphicRef70158 \" href=\"UTD.htm?31/21/32095\">",
"     picture 1",
"    </a>",
"    ). Major portions of the CNS are absent or malformed. The hypothalamus is typically missing. The cerebellum, brainstem, optic nerves, and spinal cord may be malformed. Underdevelopment or absence of the pituitary leading to adrenal hypoplasia is always present [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11237/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Large portions of the cranium are absent in this disorder. The frontal, parietal, and portions of the occipital bones are most often affected. The absent cranial vault results in the characteristic appearance of bulging eyes and absent neck. The defect in the skull sometimes extends through the level of the foramen magnum and involves the cervical spine. This abnormality is known as holoacrania [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11237/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13324810\">",
"    <span class=\"h2\">",
"     Associated malformations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other congenital malformations frequently accompany anencephaly. In a registry of 456 affected stillborn and liveborn infants in British Columbia, additional malformations, including cleft lip",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    palate or omphalocele, occurred in 12.7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11237/abstract/22\">",
"     22",
"    </a>",
"    ]. Craniofacial and ocular anomalies often occur. Cardiac, pulmonary, renal, and skeletal malformations may be associated. Aganglionosis of the intestine is a frequent finding [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11237/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13324817\">",
"    <span class=\"h2\">",
"     Neurologic function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonates with anencephaly typically have brainstem function, with spontaneous breathing and often with suck, root, and gag responses. However, they are permanently unconscious. Without intensive care, the majority of them die within two days of birth, and none survive longer than two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11237/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13324824\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 75 percent of anencephalic infants are stillborn. Liveborn infants generally die within hours but occasionally survive for a few days or weeks. There are no neurosurgical management options. In most developed countries where abortion is legal these pregnancies are interrupted earlier. Therefore, prevention is the most important aspect of management of anencephaly.",
"   </p>",
"   <p>",
"    Because of their poor prognosis, anencephalic infants have been considered as potential organ donors for transplantation. To assess the feasibility of this approach, one group modified the medical care of 12 live-born anencephalic infants for one week to determine whether organ viability could be maintained and whether the criteria of total brain death could be met. Among six anencephalic infants who received intensive care during the first week after birth, organ function was maintained, but five were not candidates for organ donation because they had persistent brainstem activity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11237/abstract/24\">",
"     24",
"    </a>",
"    ]. Among six other infants who did not receive intensive care during the first week of life, most organs were damaged, precluding organ donation. These findings suggest that anencephalic infants are not good candidates for organ donation because they do not generally meet criteria for brain death until their clinical condition has declined to the point where the solid organs are damaged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13324831\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several lines of evidence suggest a link between",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/31/22005?source=see_link\">",
"     folic acid",
"    </a>",
"    deficiency and the development of NTDs including anencephaly. Risk factors for NTDs include dietary deficiency of folic acid, administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/54/27497?source=see_link\">",
"     valproate",
"    </a>",
"    or folic acid antagonists such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/8/5255?source=see_link\">",
"     trimethoprim",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/36/5706?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/63/29689?source=see_link\">",
"     phenobarbital",
"    </a>",
"    , and genetic polymorphisms in genes encoding folate-dependent enzymes. Moreover, randomized trials have consistently shown that folic acid supplementation reduces the incidence of NTDs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/61/5081?source=see_link&amp;anchor=H3#H3\">",
"     \"Folic acid for prevention of neural tube defects\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other contributors to NTD risk that are probably not related to folate metabolism include maternal diabetes mellitus with poor glycemic control during the first trimester, hyperthermia, and some genetic syndromes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/61/5081?source=see_link&amp;anchor=H15#H15\">",
"     \"Folic acid for prevention of neural tube defects\", section on 'Treatment failures'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36281?source=see_link&amp;anchor=H4#H4\">",
"     \"Pregnancy risks in women with type 1 and type 2 diabetes mellitus\", section on 'Congenital malformations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Periconceptional",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/31/22005?source=see_link\">",
"     folic acid",
"    </a>",
"    supplementation is recommended for all women who are pregnant or who may become pregnant. Higher doses of folic acid supplements are usually recommended for women who are taking anticonvulsant drugs or who have had a previous pregnancy affected by a NTD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/61/5081?source=see_link&amp;anchor=H7#H7\">",
"     \"Folic acid for prevention of neural tube defects\", section on 'Folic acid supplementation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13325264\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anencephaly is a severe defect of development of the neuraxis, in which the developing forebrain and variable amounts of the brainstem are exposed in utero and destroyed or fail to develop (",
"      <a class=\"graphic graphic_picture graphicRef70158 \" href=\"UTD.htm?31/21/32095\">",
"       picture 1",
"      </a>",
"      ). Neonates with anencephaly typically have brainstem function but are permanently unconscious; none survive longer than two weeks. (See",
"      <a class=\"local\" href=\"#H13324817\">",
"       'Neurologic function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prenatal diagnosis of anencephaly is accomplished by maternal screening of serum alpha-fetoprotein (AFP) levels and ultrasonography. Prenatal detection usually is followed by termination of the pregnancy. (See",
"      <a class=\"local\" href=\"#H13324796\">",
"       'Prenatal diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for NTDs include dietary deficiency of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/31/22005?source=see_link\">",
"       folic acid",
"      </a>",
"      , administration of folic acid antagonists such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/8/5255?source=see_link\">",
"       trimethoprim",
"      </a>",
"      , and several types of antiepileptic drugs, and genetic polymorphisms in genes encoding folate-dependent enzymes. Folic acid supplementation given from before the time of conception reduces the incidence of NTDs and is recommended for all women who are pregnant or who may become pregnant. (See",
"      <a class=\"local\" href=\"#H13324831\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Sadler TW. Langman's Medical Embryology, Lippincott Williams &amp; Wilkins, Philadelphia 1990. p.352.",
"    </li>",
"    <li>",
"     Lemire RJ, Beckwith JB, Warkuny J. Anencephaly, Raven Press, New York 1978.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11237/abstract/3\">",
"      Stone DH. The declining prevalence of anencephalus and spina bifida: its nature, causes and implications. Dev Med Child Neurol 1987; 29:541.",
"     </a>",
"    </li>",
"    <li>",
"     O'Rahilly M, Muller F. Human Embryology &amp; Teratology, Wiley-Liss, Inc, New York 1992. p.253.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11237/abstract/5\">",
"      Sarnat HB, Flores-Sarnat L. Embryology of the neural crest: its inductive role in the neurocutaneous syndromes. J Child Neurol 2005; 20:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11237/abstract/6\">",
"      Coskun A, Kiran G, Ozdemir O. Craniorachischisis totalis: a case report and review of the literature. Fetal Diagn Ther 2009; 25:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11237/abstract/7\">",
"      Naveen N, Vishal K, Maligi A. Craniorachischisis totalis. J Neurosci Rural Pract 2010; 1:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11237/abstract/8\">",
"      Mathews TJ, Honein MA, Erickson JD. Spina bifida and anencephaly prevalence--United States, 1991-2001. MMWR Recomm Rep 2002; 51:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11237/abstract/9\">",
"      Boulet SL, Yang Q, Mai C, et al. Trends in the postfortification prevalence of spina bifida and anencephaly in the United States. Birth Defects Res A Clin Mol Teratol 2008; 82:527.",
"     </a>",
"    </li>",
"    <li>",
"     Volpe JJ. Intracranial hemorrhage: Neural tube formation and prosencephalic development. In: Neurology of the Newborn, 4th, WB Saunders, Philadelphia 2001. p.3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11237/abstract/11\">",
"      Frey L, Hauser WA. Epidemiology of neural tube defects. Epilepsia 2003; 44 Suppl 3:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11237/abstract/12\">",
"      Li Z, Ren A, Zhang L, et al. Extremely high prevalence of neural tube defects in a 4-county area in Shanxi Province, China. Birth Defects Res A Clin Mol Teratol 2006; 76:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11237/abstract/13\">",
"      Cowchock S, Ainbender E, Prescott G, et al. The recurrence risk for neural tube defects in the United States: a collaborative study. Am J Med Genet 1980; 5:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11237/abstract/14\">",
"      Toriello HV, Higgins JV. Occurrence of neural tube defects among first-, second-, and third-degree relatives of probands: results of a United States study. Am J Med Genet 1983; 15:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11237/abstract/15\">",
"      Seller MJ. Recurrence risks for neural tube defects in a genetic counseling clinic population. J Med Genet 1981; 18:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11237/abstract/16\">",
"      Czeizel A, M&eacute;tneki J. Recurrence risk after neural tube defects in a genetic counselling clinic. J Med Genet 1984; 21:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11237/abstract/17\">",
"      Koch M, Fuhrmann W. Sibs of probands with neural tube defects--a study in the Federal Republic of Germany. Hum Genet 1985; 70:74.",
"     </a>",
"    </li>",
"    <li>",
"     Nussbaum R, McInnes RR, Willard HF. Genetics of disorders with complex inheritance. In: Thompson &amp; Thompson Genetics in Medicine, 6, WB Saunders, Philadelphia 2001. p.289.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11237/abstract/19\">",
"      MacCarthy PA, Dalrymple IJ, Duignan NM, et al. Recurrence rates of neural tube defects in Dublin maternity hospitals. Ir Med J 1983; 76:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11237/abstract/20\">",
"      Copp AJ, Greene ND. Genetics and development of neural tube defects. J Pathol 2010; 220:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11237/abstract/21\">",
"      Mazzitelli N, Vauthay L, Grandi C, et al. Reviewing old concepts at the start of a new millenium: growth restriction, adrenal hypoplasia, and thymomegaly in human anencephaly. Teratology 2002; 66:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11237/abstract/22\">",
"      Sadovnick AD, Baird PA. Congenital malformations associated with anencephaly in liveborn and stillborn infants. Teratology 1985; 32:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11237/abstract/23\">",
"      Mathew A. Anencephaly-associated aganglionosis. Am J Med Genet 1998; 80:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11237/abstract/24\">",
"      Peabody JL, Emery JR, Ashwal S. Experience with anencephalic infants as prospective organ donors. N Engl J Med 1989; 321:344.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16869 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-41.78.124.10-9FDBE1AB85-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_62_11237=[""].join("\n");
var outline_f10_62_11237=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13325264\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13323850\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13324094\">",
"      EMBRYOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13324782\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13324789\">",
"      RECURRENCE RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13324796\">",
"      PRENATAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13324803\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13324810\">",
"      Associated malformations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13324817\">",
"      Neurologic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13324824\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13324831\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13325264\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/16869\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/16869|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/24/20879\" title=\"figure 1\">",
"      Cephalocaudad neurulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/16869|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/21/32095\" title=\"picture 1\">",
"      Anencephaly",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/61/5081?source=related_link\">",
"      Folic acid for prevention of neural tube defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26344?source=related_link\">",
"      Overview of the management of myelomeningocele (spina bifida)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20921?source=related_link\">",
"      Pathogenesis and types of occult spinal dysraphism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33767?source=related_link\">",
"      Pathophysiology and clinical manifestations of myelomeningocele (spina bifida)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36281?source=related_link\">",
"      Pregnancy risks in women with type 1 and type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3991?source=related_link\">",
"      Primary (congenital) encephalocele",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35560?source=related_link\">",
"      Ultrasound diagnosis of neural tube defects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_62_11238="Evaluation of a child with glomerular disease";
var content_f10_62_11238=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of a child with glomerular disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/62/11238/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/62/11238/contributors\">",
"     Patrick Niaudet, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/62/11238/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/62/11238/contributors\">",
"     F Bruder Stapleton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/62/11238/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/62/11238/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/62/11238/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are numerous causes of glomerular diseases in children. Many of these conditions vary in their presentation with mild or no symptoms to serious renal disease with life-threatening complications. As a result, the diagnosis of a specific glomerular disease is challenging in children but important so that therapy, if helpful and needed, can be initiated.",
"   </p>",
"   <p>",
"    The diagnostic evaluation of children with glomerular disease will be reviewed here. The evaluation of children with nonglomerular causes of isolated hematuria or proteinuria is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/55/30584?source=see_link\">",
"     \"Evaluation of microscopic hematuria in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1127?source=see_link\">",
"     \"Evaluation of gross hematuria in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26262?source=see_link\">",
"     \"Evaluation of proteinuria in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous primary (renal disease alone) and secondary (due to systemic autoimmune disorders, vasculitis, or infection) disorders produce glomerular disease (",
"    <a class=\"graphic graphic_table graphicRef52094 \" href=\"UTD.htm?22/47/23291\">",
"     table 1",
"    </a>",
"    ). Dividing childhood glomerular diseases into two clinical patterns (although there is overlap in some diseases) is useful because the evaluation can focus on the most likely underlying disease. The initial evaluation determines the pattern of glomerular disease, and the second stage of evaluation depends upon the identified primary pattern of glomerular disease: nephritic or nephrotic presentation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A nephritic pattern is associated with inflammation on histologic examination and produces an active urine sediment with red cells, white cells, granular and often red cell and other cellular casts, and a variable degree of proteinuria. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/1/12311?source=see_link\">",
"       \"Overview of the pathogenesis and causes of glomerulonephritis in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35304?source=see_link\">",
"       \"Poststreptococcal glomerulonephritis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A nephrotic pattern, which is not associated with inflammation on histologic examination, presents with nephrotic range proteinuria, and an inactive urine sediment with few cells or casts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both patterns can present with an acute or insidious time course, and elements of both may be also seen in some patients simultaneously or sequentially. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link\">",
"     \"Differential diagnosis and evaluation of glomerular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations, urinalysis, and the rate of protein excretion divide children with glomerular disease into two groups: patients with nephritic syndrome and those with nephrotic syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephritic syndrome is characterized by a constellation of findings that includes edema, hypertension, reddish-brown to brown-colored urine, and a rising serum creatinine. In severe cases, nephrotic patients may have anasarca with ascites, and respiratory distress caused by pleural effusions. Patients with both glomerulonephritis and nephrotic syndrome have an overlap of clinical findings.",
"   </p>",
"   <p>",
"    Patients with secondary causes of glomerular disease often have nonrenal symptoms and signs (eg, fever, arthralgias, rash, and pulmonary hemorrhage) that are suggestive of a specific underlying systemic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Urinalysis and urinary protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing of the urine is the most important noninvasive test in determining whether or not a child has glomerular disease, and if present, distinguishes between the two patterns of glomerular disease. Children who have evidence of glomerular bleeding are likely to have nephritic syndrome secondary to glomerulonephritis, and those with heavy proteinuria are likely to have nephrotic syndrome.",
"   </p>",
"   <p>",
"    The following urinalysis findings, if present, are indicative of glomerular bleeding and glomerulonephritis. However, the absence of these findings does not exclude glomerulonephritis (",
"    <a class=\"graphic graphic_table graphicRef65786 \" href=\"UTD.htm?6/26/6571\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Red cell casts (pathognomonic for glomerular bleeding) (",
"      <a class=\"graphic graphic_picture graphicRef55778 \" href=\"UTD.htm?34/38/35424\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Red blood cells that are dysmorphic in appearance (",
"      <a class=\"graphic graphic_picture graphicRef79440 graphicRef62064 \" href=\"UTD.htm?40/13/41170\">",
"       picture 2A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Protein excretion greater than 100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day at a time when there is no gross bleeding",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, the urinalysis of children with nephrotic syndrome is associated with heavy proteinuria and lipiduria but few cells or cast. Although the urinary dipstick measurement is a qualitative test, a 4+ recording, which corresponds to a concentration of urinary albumin of 1000",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    is suggestive of nephrotic range proteinuria, defined as a urinary protein excretion greater than 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day or 40",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per hour.",
"   </p>",
"   <p>",
"    Nephrotic range proteinuria is confirmed by a quantitative measurement of a timed 24-hour urine collection or by measuring the total",
"    <span class=\"nowrap\">",
"     protein/creatinine",
"    </span>",
"    ratio on a spot urine sample (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?16/18/16673?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). The urine sample should be a first morning void to exclude the possibility of orthostatic proteinuria. The ratio that is indicative of nephrotic range proteinuria is greater than 3 mg",
"    <span class=\"nowrap\">",
"     protein/mg",
"    </span>",
"    creatinine (300 mg",
"    <span class=\"nowrap\">",
"     protein/mmol",
"    </span>",
"    creatinine). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37432?source=see_link&amp;anchor=H13#H13\">",
"     \"Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children\", section on 'Urine protein excretion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Renal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once glomerular disease is identified, the presence or degree of renal dysfunction is assessed by an estimation of the glomerular filtration rate. A reduction in GFR implies either progression of the underlying disease or the development of a superimposed and often reversible problem, such as decreased renal perfusion due to volume depletion.",
"   </p>",
"   <p>",
"    The most common methods utilized to estimate the GFR is the serum creatinine concentration, and the estimation of creatinine clearance based upon the serum creatinine.",
"   </p>",
"   <p>",
"    Developed in the 1970s, the Schwartz formula is the method currently most often used to estimate GFR in children and adolescents. The original formula was based upon serum creatinine determined by the Jaffe method, height, and an aged based constant k that varied with age (and in adolescents the gender of the patient) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11238/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?23/40/24193?source=see_link\">",
"     calculator 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    &nbsp;GFR = k X Height (cm)",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    Screat (Jaffe method)",
"   </p>",
"   <p>",
"    Height represents the body height measured in centimeters, and Screat is the serum creatinine value in",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    as determined by the Jaffe method. The constant k is directly proportional to the muscle component of body, and varies with age. The value for k is 0.33 in premature infants through the first year of life, 0.45 for term infants through the first year of life, 0.55 in children and adolescent girls, and 0.7 in adolescent boys.",
"   </p>",
"   <p>",
"    However, the now commonly used enzymatic method for creatinine determination results in a lower value of creatinine compared to the older Jaffe method; thus, the Schwartz formula generally overestimates GFR compared to measured values. As a result, ongoing efforts are focused on finding a more accurate estimate of GFR than the Schwartz formula from easily obtainable blood tests in children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11418?source=see_link&amp;anchor=H26#H26\">",
"     \"Clinical presentation and evaluation of chronic kidney disease in children\", section on 'Serum creatinine and GFR'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     FURTHER EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the initial evaluation, the child's glomerular disease is categorized as either nephritic syndrome or nephrotic syndrome. The clinical distinction between the two is a starting point to form an initial differential diagnosis and to direct further evaluation to determine the underlying glomerular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11238/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with both nephritic and nephrotic syndrome are evaluated in a similar manner to those with nephritic syndrome because several of the glomerulonephritides may also present with nephrotic syndrome, whereas idiopathic nephrotic syndrome does not typically have an inflammatory component. In addition, patients who are suspected of having glomerular disease but don't fit either category are also included in the glomerulonephritis category, as they are likely to have a mild course of a glomerulonephritis. For example, children who present with recurrent gross hematuria after an upper respiratory infection without an active sediment or proteinuria may have a mild course of IgA nephropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Glomerulonephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glomerulonephritis represents a variety of disorders that are caused by immunologic injury that results in inflammation of the glomeruli. These disorders may be primary (only renal involvement) or secondary (due to systemic disease or infection) (",
"    <a class=\"graphic graphic_table graphicRef52094 \" href=\"UTD.htm?22/47/23291\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/1/12311?source=see_link\">",
"     \"Overview of the pathogenesis and causes of glomerulonephritis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Blood tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of nephritic syndrome in children focuses on identifying the underlying diagnosis and includes the following diagnostic blood tests (",
"    <a class=\"graphic graphic_algorithm graphicRef74379 \" href=\"UTD.htm?25/4/25670\">",
"     algorithm 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serologic testing to screen for a recent antecedent streptococcal infection (ie, anti-streptolysin, anti-hyaluronidase, anti-streptokinase, anti-nicotinamide-adenine dinucleotidase, and anti-DNAse B antibodies). Positive serology indicates a recent streptococcal infection, and fulfills a criterion for the diagnosis of poststreptococcal glomerulonephritis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35304?source=see_link&amp;anchor=H14#H14\">",
"       \"Poststreptococcal glomerulonephritis in children\", section on 'Serology'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35304?source=see_link&amp;anchor=H15#H15\">",
"       \"Poststreptococcal glomerulonephritis in children\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antinuclear antibodies (ANA) and antiDNA antibodies &mdash; An elevated ANA titer or antiDNA antibody titer fulfills one of the eleven criteria for the diagnosis of systemic lupus erythematosus (",
"      <a class=\"graphic graphic_table graphicRef73334 \" href=\"UTD.htm?2/47/2813\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10810?source=see_link&amp;anchor=H10#H10\">",
"       \"Systemic lupus erythematosus in children\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Complement studies including C3, C4, and CH50.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Low C3 levels due to activation of the alternative pathway of complement are associated with poststreptococcal (PSGN) and membranoproliferative glomerulonephritis (MPGN) II, also referred to as dense deposit disease. The C3 levels typically return to normal within four to six weeks of presentation in patients with PSGN, whereas they remain persistently low in patients with MPGN. (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35304?source=see_link&amp;anchor=H12#H12\">",
"       \"Poststreptococcal glomerulonephritis in children\", section on 'Complement'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=see_link\">",
"       \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Low C3 and C4 levels are due to activation of the classic pathway due to immune complex formation. This combination of hypocomplementemia is seen in lupus nephritis, MPGN I, shunt nephritis, and nephritis associated with subacute bacterial endocarditis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/54/29542?source=see_link&amp;anchor=H3#H3\">",
"       \"Acquired disorders of the complement system\", section on 'Systemic lupus erythematosus'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/27/5556?source=see_link&amp;anchor=H2#H2\">",
"       \"Renal disease in the setting of infective endocarditis or an infected ventriculoatrial shunt\", section on 'Glomerulonephritis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antineutrophil cytoplasmic antibodies (ANCA) &mdash; ANCA are detected in patients with pauci-immune glomerulonephritis that are seen in patients with systemic vasculitis, such as granulomatosis with polyangiitis (formerly referred to as Wegener's granulomatosis). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link\">",
"       \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other blood tests that can be performed based upon clinical presentation, the results of previous testing, and the clinical judgment of the clinician include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      IgA levels may be elevated in patients with IgA nephropathy or Henoch-Sch&ouml;nlein purpura. A promising assay that screens for antibodies to galactose-deficient IgA1 may, in the future, be helpful in diagnosing IgA nephropathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1337?source=see_link&amp;anchor=H12#H12\">",
"       \"Clinical presentation and diagnosis of IgA nephropathy\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serologic testing for Epstein-Barr virus, or hepatitis B and C.",
"     </li>",
"     <li>",
"      Antiglomerular basement membrane (GBM) antibody screening, especially in a child with concurrent pulmonary symptoms, may be help in diagnosing anti-glomerular based membrane disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4409?source=see_link&amp;anchor=H8#H8\">",
"       \"Pathogenesis and diagnosis of anti-GBM antibody (Goodpasture's) disease\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Renal biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A renal biopsy is performed to confirm a diagnosis, determine the extent of renal injury,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    predict renal outcome. The timing of a renal biopsy is dependent upon the clinical setting. In patients with rapidly progressive glomerulonephritis, which is rare in children, early diagnosis with renal biopsy and serologic testing, and early initiation of appropriate therapy are essential to minimize the degree of irreversible renal injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/1/12311?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of the pathogenesis and causes of glomerulonephritis in children\", section on 'Rapidly progressive GN'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18231?source=see_link\">",
"     \"Overview of the classification and treatment of rapidly progressive (crescentic) glomerulonephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nephrotic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrotic syndrome in children is classified into three categories. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37432?source=see_link&amp;anchor=H5#H5\">",
"     \"Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary nephrotic syndrome, which refers to nephrotic syndrome in the absence of an identifiable systemic disease",
"     </li>",
"     <li>",
"      Secondary nephrotic syndrome, which refers to nephrotic syndrome in the presence of an identifiable systemic disease",
"     </li>",
"     <li>",
"      Congenital and infantile nephrotic syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7753?source=see_link\">",
"       \"Congenital and infantile nephrotic syndrome\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In particular, both primary and secondary nephrotic syndromes include patients with glomerulonephritis, who have an active sediment and glomerular inflammation on renal biopsy. The evaluation of these patients is the same as that of a child with glomerulonephritis alone. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Glomerulonephritis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The diagnostic evaluation of children with only nephrotic syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37432?source=see_link&amp;anchor=H11#H11\">",
"     \"Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous primary (renal disease alone) and secondary (eg, systemic autoimmune disorders, vasculitis, or infection) disorders produce glomerular disease in children (",
"    <a class=\"graphic graphic_table graphicRef52094 \" href=\"UTD.htm?22/47/23291\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical manifestations, urinalysis, and the rate of protein excretion divide children with glomerular disease into two groups: patients with nephritic syndrome, and those with nephrotic syndrome. In both groups, renal function is assessed by measuring the serum creatinine. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Initial evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with nephritic syndrome typically will present with edema, hypertension, reddish brown to brown colored urine, and a rising serum creatinine. Urinalysis findings include evidence of glomerular bleeding, such as red cell cells and red cell casts (",
"      <a class=\"graphic graphic_picture graphicRef55778 \" href=\"UTD.htm?34/38/35424\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef79440 graphicRef62064 \" href=\"UTD.htm?40/13/41170\">",
"       picture 2A-B",
"      </a>",
"      ). Patients generally have proteinuria greater than 100",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      per day, when there is no gross hematuria. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Initial evaluation'",
"      </a>",
"      above.)&nbsp;(See",
"      <a class=\"local\" href=\"#H3\">",
"       'Initial evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Further evaluation of children with nephritic syndrome includes serologic testing for a recent streptococcal infection, antinuclear antibodies (ANA) and antiDNA antibodies, complement studies, and antineutrophil cytoplasmic antibodies (ANCA). A renal biopsy is performed to confirm a diagnosis, determine the extent of renal injury,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      predict renal outcome. The timing of a renal biopsy is dependent upon the clinical setting. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Glomerulonephritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with nephrotic syndrome typically present only with edema, an inactive urine sediment (ie, few or no red blood cells, and cellular casts), and nephrotic range proteinuria, defined as a urinary protein excretion greater than 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day or 40",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      per hour. The diagnostic evaluation of children with nephrotic syndrome is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37432?source=see_link&amp;anchor=H11#H11\">",
"       \"Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with both nephritic and nephrotic syndromes are evaluated in a similar manner to those with nephritic syndrome, because many of the glomerulonephritides also present with nephrotic syndrome. Whereas, idiopathic nephrotic syndrome does not typically have an inflammatory component. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Further evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11238/abstract/1\">",
"      Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 1987; 34:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11238/abstract/2\">",
"      Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976; 58:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11238/abstract/3\">",
"      Counahan R, Chantler C, Ghazali S, et al. Estimation of glomerular filtration rate from plasma creatinine concentration in children. Arch Dis Child 1976; 51:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11238/abstract/4\">",
"      Madaio MP, Harrington JT. The diagnosis of glomerular diseases: acute glomerulonephritis and the nephrotic syndrome. Arch Intern Med 2001; 161:25.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6119 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-12B1265D54-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_62_11238=[""].join("\n");
var outline_f10_62_11238=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Urinalysis and urinary protein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Renal function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      FURTHER EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Blood tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Renal biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6119\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6119|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?25/4/25670\" title=\"algorithm 1\">",
"      Dx GN child serology IFM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6119|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/38/35424\" title=\"picture 1\">",
"      Photomicrograph of urine sediment with a red cell cast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/0/24591\" title=\"picture 2A\">",
"      Phase contrast micrograph showing dysmorphic red cells in urine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/47/14079\" title=\"picture 2B\">",
"      Scanning electron micrograph showing dysmorphic red cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6119|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/47/23291\" title=\"table 1\">",
"      Primary secondary GN child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/26/6571\" title=\"table 2\">",
"      Glomerular v extraglom in child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/47/2813\" title=\"table 3\">",
"      ACR criteria for SLE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?16/18/16673?source=related_link\" title=\"calculator 1\">",
"      Calculator: Urinary protein excretion estimation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?23/40/24193?source=related_link\" title=\"calculator 2\">",
"      Calculator: Glomerular filtration rate estimate by Schwartz formula",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/54/29542?source=related_link\">",
"      Acquired disorders of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1337?source=related_link\">",
"      Clinical presentation and diagnosis of IgA nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11418?source=related_link\">",
"      Clinical presentation and evaluation of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=related_link\">",
"      Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7753?source=related_link\">",
"      Congenital and infantile nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37432?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1127?source=related_link\">",
"      Evaluation of gross hematuria in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/55/30584?source=related_link\">",
"      Evaluation of microscopic hematuria in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26262?source=related_link\">",
"      Evaluation of proteinuria in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18231?source=related_link\">",
"      Overview of the classification and treatment of rapidly progressive (crescentic) glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/1/12311?source=related_link\">",
"      Overview of the pathogenesis and causes of glomerulonephritis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4409?source=related_link\">",
"      Pathogenesis and diagnosis of anti-GBM antibody (Goodpasture's) disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35304?source=related_link\">",
"      Poststreptococcal glomerulonephritis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/27/5556?source=related_link\">",
"      Renal disease in the setting of infective endocarditis or an infected ventriculoatrial shunt",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10810?source=related_link\">",
"      Systemic lupus erythematosus in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_62_11239="Grovers histology";
var content_f10_62_11239=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F56584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F56584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Histology of Grover's disease (transient and persistent acantholytic dermatosis)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 342px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Histopathology demonstrates acantholytic keratinocytes leading to suprabasilar clefting. Dyskeratotic keratinocytes extend from the mid-epidermis to the stratum corneum. Hemorrhage is noted in the intraepidermal cleft secondary to the mechanical trauma of repeated scratching. (H&amp;E staining, original magnification 400x).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Whitney High, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_62_11239=[""].join("\n");
var outline_f10_62_11239=null;
var title_f10_62_11240="The kidney transplant waiting list";
var content_f10_62_11240=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The kidney transplant waiting list",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/62/11240/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/62/11240/contributors\">",
"     Gabriel Danovitch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/62/11240/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/62/11240/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/62/11240/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/62/11240/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/62/11240/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As of late 2010, a total of approximately 93,000 patients were registered on the kidney transplant waiting list at the United Network for Organ Sharing (UNOS) in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Registration on this list by individual transplant programs is required before a patient can be allocated a deceased donor organ. Over 30 percent of the list is registered in an \"inactive\" status, the significance of which will be discussed below.",
"   </p>",
"   <p>",
"    This topic review will discuss the composition of and access to the kidney transplant waitlist, as well as the management of patients while they await allocation of a kidney. Additional information is available elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/1,3-5\">",
"     1,3-5",
"    </a>",
"    ], and on the UNOS web site, which can be found at the web address:",
"    <a class=\"external\" href=\"file://www.unos.org/\">",
"     www.UNOS.org",
"    </a>",
"   </p>",
"   <p>",
"    The details of the allocation algorithm for deceased donor kidneys and issues related to the evaluation of the kidney transplant candidate, including the possible presence of coronary disease, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26490?source=see_link\">",
"     \"Evaluation of the potential renal transplant recipient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/7/5240?source=see_link\">",
"     \"Organ sharing in kidney transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THE ACTIVE AND INACTIVE LIST",
"    </span>",
"    &nbsp;&mdash;&nbsp;The kidney transplant waiting list in the United States had been expanding by 3000 to 4000 patients each year [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/4\">",
"     4",
"    </a>",
"    ]. However, the steady increase in the number of so-called active candidates has slowed, and since 2001, this number has been stable at approximately 50,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Current policy permits inactive candidates (also called \"status 7\") to accrue waiting time points; however, only active patients are allocated transplants. The purpose of this policy is to encourage transparency in listing so that the active transplant list truly reflects candidates who are prepared for imminent transplantation. Candidates are placed in an inactive status if an inter-current condition develops that makes transplantation temporarily inadvisable (eg, during a hiatus after a treated malignancy while on the waiting list), although it is likely that some patients remain on the list despite conditions that are not reversible or while their initial work-up is being completed.",
"   </p>",
"   <p>",
"    The rate of expansion of the list reflects the number of new registrants minus the number of patients who are transplanted from living and deceased donors and the number of patients who die while awaiting a transplant or who are removed from the list for other reasons. Currently, the number of transplants performed approximates the number of new active candidates on the list.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DEMOGRAPHICS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The waiting list in the United States consists of an increasing absolute number and relative proportion of older patients. In the years between 1999 and 2008, there was a little less than a two-fold increase in the percent representation of wait list candidates older than 65 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/2\">",
"     2",
"    </a>",
"    ] and approximately 200 patients over the age of 80 were transplanted during this period [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/6\">",
"     6",
"    </a>",
"    ]. Access to transplantation for ESRD patients aged 60 to 75 has approximately doubled between 1995 and 2006 due largely to an increase in living donor transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By comparison, the proportion of active younger candidates decreased over this time period:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those less than 35 years of age represented 18 and 12 percent of the list in 1999 and 2008, respectively.",
"     </li>",
"     <li>",
"      Those between 35 and 49 years represented 35 and 29 percent of the list in 1999 and 2008, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The steady rise in both the absolute number and percentage of older patients newly registered and on the list means that, with the current allocation algorithm, younger adults are competing for kidneys with increasingly larger numbers of older patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/29/43480?source=see_link\">",
"     \"Renal transplantation and the elderly patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The anticipated waiting time for a transplant (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Waiting time'",
"    </a>",
"    below) should be considered in the decision to waitlist individual elderly patients who may have poor lifespan prognoses on dialysis. It has been estimated that half of kidney transplant candidates who are older than 60 years now placed on the waiting list will die before receiving a deceased donor transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ethnicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ratio of Caucasian to African-American listed registrants has remained unchanged over the last decade [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/4\">",
"     4",
"    </a>",
"    ]. African-Americans account for approximately 35 percent of listed registrants; this is similar to their representation in the chronic dialysis population and is approximately three fold higher than their frequency in the general population. African-Americans account for approximately 30 percent of new registrants. The higher percentage of African-Americans on the list compared to those newly listed (35 versus 30 percent) is accounted for by their slower rate of transplantation.",
"   </p>",
"   <p>",
"    The situation is reversed for Caucasians (54 and 63 percent of the existing list and newly listed registrants, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/4\">",
"     4",
"    </a>",
"    ]. This reflects their higher rate of transplantation. As of 2003, 17 percent of both listed registrants and new registrants were Hispanic or Latino.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Gender and blood group",
"    </span>",
"    &nbsp;&mdash;&nbsp;Representation of males remains approximately 15 percent greater than females [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/4\">",
"     4",
"    </a>",
"    ]. Blood group O registrants consistently comprise more than 50 percent of the list.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Renal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative proportion of waitlisted registrants with a specific primary renal diagnosis does not parallel the proportion of patients receiving chronic dialysis with the same primary diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients designated as diabetic or hypertensive account for 40 and 28 percent of the dialysis population, but only 28 and 21 percent of waitlisted registrants.",
"     </li>",
"     <li>",
"      By comparison, patients designated as suffering from glomerular diseases and autosomal dominant polycystic kidney disease (PKD) account for 12 and 3 percent of the chronic dialysis population and for 21 and 6 percent of waitlisted registrants, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These discrepancies exist because hypertension and diabetes are more likely to be diagnosed in older patients with comorbid conditions that may exclude them from transplantation. Patients with glomerular diseases and PKD are likely to be younger with fewer comorbidities that preclude transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     LISTING PRACTICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the survival advantage of kidney transplantation extends to many high-risk ESRD patients, numerous factors ultimately determine which patients are evaluated and listed for the procedure. The purpose of the evaluation process for transplant candidacy is to identify patients who will benefit from transplantation and exclude patients who might be placed at risk, yet actual listing practices and policies vary widely between centers.",
"   </p>",
"   <p>",
"    In a study estimating the life expectancy of adult patients in the United States prior to transplantation with ESRD, factors associated with transplant listing were examined based on patient prognosis after ESRD [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/10\">",
"     10",
"    </a>",
"    ]. Approximately one-third of patients listed for transplantation within one year of ESRD had a life expectancy less than or equal to five years on dialysis. In contrast, one-third of patients not listed had a life expectancy greater than five years. The number of patients not listed with \"good\" prognosis was significantly higher than those listed with \"poor\" prognosis. Age, race, gender, insurance coverage and body mass index (BMI) were associated with likelihood for listing with \"poor\" prognosis and not listing with \"good\" prognosis. Hence, many ESRD patients viable for transplantation are not listed for transplantation while higher-risk patients have listed rapidly. The reasons for these discrepancies are not well-explained, and they are not confined to transplantation practice in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     WAITING TIME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The median time to transplant for new candidates (indicating the number of days by which 50 percent of these patients have been transplanted) has ranged around 1100 to 1200 days [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/1\">",
"     1",
"    </a>",
"    ]. Waiting time for white candidates is approximately 40 percent less than all other races.",
"   </p>",
"   <p>",
"    The time to transplant also varies among blood types. Blood groups AB, A, O, and B have mean wait times of 2, 3, 5, and 6 years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, blood group O and B patients wait the longest.",
"   </p>",
"   <p>",
"    The waiting time for non-resident aliens does not differ from that of United States citizens [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Previously transplanted and presensitized patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Presensitization describes the development of antibodies against histocompatibility antigens as a result of blood transfusion, pregnancy, and prior failed transplants. These antibodies, termed panel reactive antibodies (PRA), are detected by incubating the patient's serum with a panel of antigens developed from the general population.",
"   </p>",
"   <p>",
"    Patients with high levels of PRA have difficulty achieving a negative crossmatch and wait approximately twice as long for a transplant as those with a low PRA. As a group, previously transplanted patients wait approximately twice as long as those awaiting a first transplant. However, for previously transplanted registrants with a low PRA, there is little difference in the time to transplant.",
"   </p>",
"   <p>",
"    The familiar PRA is being replaced by a \"virtual crossmatch\" or calculated PRA (CPRA) test whereby specific donor HLA antigens are identified in the waitlisted recipient and reported to UNOS if it is determined that they are likely to engender a positive crossmatch. This permits anticipation of the crossmatch result and avoids unnecessary testing, expense, and loss of time. This topic, together with issues surrounding attempts to lower HLA antibody levels in patients with very high PRA levels are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34570?source=see_link\">",
"     \"HLA and ABO sensitization and desensitization in renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DEATH ON THE WAITING LIST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall mortality on the waiting list is approximately 6 percent per year, with a higher estimate of 10 percent per year for diabetic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/5,13,14\">",
"     5,13,14",
"    </a>",
"    ]. The death rate increases with age. For the years 2000 to 2003, the death rate was approximately 30 deaths per 1,000 patient years at risk for patients aged 18 to 34 years, which increased progressively to 100 deaths per 1,000 patient years at risk for patients ages greater than 65 years [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, a patient over the age of 60 years who will need to wait five years for a kidney has an approximately 50 percent chance of dying before a kidney becomes available [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/5,9\">",
"     5,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Currently, approximately half of the deaths on the waiting list occur in patients who are on inactive status. This has increased markedly over the last several years, as 30 percent of waiting list deaths were noted among those with inactive status in 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mortality rate on the waitlist is approximately twofold higher than in patients on the list who receive a kidney from a living donor or a standard criteria deceased donor. For the recipient of an expanded (or extended) criteria donor (ECD) kidney (which is a lesser quality kidney), the mortality rate reduction is approximately one-third less. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/7/5240?source=see_link\">",
"     \"Organ sharing in kidney transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Expanded donor kidneys",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expanded criteria donor (ECD) kidneys are those from either a brain-dead donor older than 60 years, or a donor older than 50 years with at least two of the following: hypertension, serum creatinine greater than 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (133",
"    <span class=\"nowrap\">",
"     &micro;mol/L),",
"    </span>",
"    or cerebrovascular cause of death [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/16\">",
"     16",
"    </a>",
"    ]. Patients who agree to be placed on the list waiting for an ECD kidney are also eligible to receive standard donor kidneys. As a result, it may be difficult for patients to decide whether to accept an ECD kidney and have a decreased time on the waitlist or to stay a longer time on the waitlist and eventually receive a standard criteria deceased donor kidney. This dilemma is most typically faced by older patients. Expressed simply the question is: is it better to accept an ECD kidney after a short wait or a standard criteria donor kidney after a longer wait?",
"   </p>",
"   <p>",
"    The answer to this question depends to a large extent on patient age and also on the anticipated waiting time for a deceased donor kidney in their graphical area. Quality of life with maintenance dialysis is a highly subjective factor that individual patients and their advocates should take into account in their decision-making process.",
"   </p>",
"   <p>",
"    Based upon patient age, there may be a survival advantage or disadvantage to waiting longer for a living donor or standard criteria deceased donor kidney compared with a shorter wait for an ECD kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/17\">",
"     17",
"    </a>",
"    ]. This was best shown in a study of all adult renal transplant candidates and recipients in the United States in the period from 1995 to 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/18\">",
"     18",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients aged 18 to 39 years, there was a longer life expectancy with receiving a living donor (27.6 years) or standard criteria donor (26.4 years) kidney after four years of dialysis versus an ECD kidney (17.6 years) after two years of dialysis.",
"     </li>",
"     <li>",
"      By comparison, for patients greater than 65 years of age, life expectancy was slightly higher with an ECD kidney (5.6 years) after two years of dialysis versus a standard (5.3 years) or living donor (5.5 years) kidney after four years of dialysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In an analysis of 145,470 recipients identified from the Scientific Registry of Transplant Recipients (SRTR) database, compared with non-ECD kidneys, ECD kidneys were associated with higher mortality among recipients between the ages of 18 to 35 years (HR 1.46, 95% CI 1.19-1.77), 35 to 55 years (HR 1.23, 95% CI 1.14-1.32), and 55 to 65 years (HR 1.26, 95% CI, 1.15-1.38), and among patients 65 to 70 years (HR 1.20, 95% CI 1.05-1.36) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/19\">",
"     19",
"    </a>",
"    ]. ECD-kidneys were not associated with a significantly increased mortality among patients between ages 70 to &lt;75 years (HR of 1.12, 95% CI 0.93-1.36) or those 75 years or older (HR 1.04, 95% CI 0.74-1.47). Similar results were found for risk of transplant loss. However, in one single-center study in which the mean waitlist time was under two years, among patients 60 years of age or older, transplantation of an ECD kidney was associated with higher mortality compared with transplantation of a standard criteria kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hence, for younger patients it is generally worth waiting for a higher quality kidney. For older patients a prolonged wait for a standard criteria kidney is not in their interest. However, if older patients are fortunate to live in a geographical area of the US where waiting times are relatively short then it may be in their interest to wait somewhat longer for the higher quality organ.",
"   </p>",
"   <p>",
"    The complexity of this decision process requires that older patients be given ample opportunity to make an informed decision with which they are comfortable.",
"   </p>",
"   <p>",
"    Overall, patients of all ages and diagnoses who are on the waiting list benefit from the reduced relative mortality of transplantation, including those who require a prolonged wait for a kidney. Patients with a lower life expectancy can anticipate a lesser absolute gain in life-years from transplantation. A detailed discussion of these issues is available in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17992?source=see_link\">",
"     \"Patient survival after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ACCESS TO THE WAITING LIST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deceased donor transplantation requires access to the waiting list, which in turn requires access to a transplant center. Optimal outcomes occur when kidney transplantation is performed as early as possible after the development of advanced chronic kidney disease (CKD), preferably before dialysis is required (preemptive transplantation). Unfortunately, most CKD patients do not see a nephrologist until late in the disease course [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/21\">",
"     21",
"    </a>",
"    ]. Thus, because of the prolonged wait for a kidney, preemptive transplantation from a deceased donor is only an option for a small proportion of CKD patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11224?source=see_link\">",
"     \"Dialysis issues prior to and after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of variables have been reported to inhibit timely referral to transplantation. These include [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lower level of educational attainment",
"     </li>",
"     <li>",
"      Lower socioeconomic status",
"     </li>",
"     <li>",
"      Non-English-speaking background",
"     </li>",
"     <li>",
"      Minority race",
"     </li>",
"     <li>",
"      Female gender",
"     </li>",
"     <li>",
"      Dialysis in for profit or isolated dialysis units",
"     </li>",
"     <li>",
"      Certain medical diagnoses, such as diabetes mellitus",
"     </li>",
"     <li>",
"      Obesity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26490?source=see_link\">",
"     \"Evaluation of the potential renal transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To minimize delays, patient and professional education about the benefits of early referral for transplantation is critical. For predialysis patients, early referral provides an opportunity to determine if a living donor is available and if the donor work-up can be completed expeditiously. This may facilitate the performance of preemptive transplantation and avoid access placement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30697?source=see_link\">",
"     \"Evaluation of the living kidney donor and risk of donor nephrectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early referral and listing also exposes patients to the possibility of being offered a zero-mismatch deceased donor kidney. These kidneys are allocated independent of waiting time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/7/5240?source=see_link\">",
"     \"Organ sharing in kidney transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     UNPREDICTABILITY OF ALLOCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deceased donor transplantation is unique among surgical procedures in that it is an urgent procedure performed in an elective population. Because of the inclusion of histocompatibility matching in the allocation algorithm, it has not been possible to accurately determine when a given patient will be called for transplantation.",
"   </p>",
"   <p>",
"    This unpredictability has presented transplant programs with the formidable challenge of attempting to ensure that large numbers of patients, most of whom are",
"    <strong>",
"     not",
"    </strong>",
"    under their direct care, are medically cleared for transplant at all times. It has also been difficult for patients and their caregivers to know when a kidney is likely to be offered [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Over the last few years, the following changes in the kidney allocation algorithm have somewhat alleviated this unpredictability:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extended criteria donor kidneys are allocated based upon waiting time alone. It is therefore possible to predictably determine, for each blood group, the first person on the waiting list.",
"     </li>",
"     <li>",
"      Standard criteria donor kidneys are allocated based upon waiting time (one point per year) and HLA DR matching (maximum of two points, which is equivalent to two years of waiting). As a result, patients within the top two years of the waiting list for each blood group most commonly receive these kidneys.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/7/5240?source=see_link\">",
"     \"Organ sharing in kidney transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The kidney transplant allocation algorithm is undergoing review and evaluation and will likely be extensively modified in a manner that deemphasizes waiting time. A new parameter, the incremental life-years gained from transplantation (LYFT) compared to dialysis, has been proposed with a view to prioritize those waitlisted patients with greater medical urgency and those with the best expected post-transplant survival [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     HEALTH MAINTENANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Preventive health measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients on the active transplant list can be called for a transplant at any time. As a result, every effort must be made to optimize their health according to best practices and published clinical practice guidelines. In parallel, dialysis units, nephrologists, and the patients themselves must keep transplant programs appraised of major developments in the patient's health that could be relevant to their transplant candidacy and post-transplant management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cardiovascular testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the prevalence of clinically silent coronary heart disease and increased incidence of adverse cardiovascular events in renal transplant recipients, cardiovascular evaluation has been deemed to be a critical part of the assessment of all transplant candidates. Diabetic patients are at particular risk of an adverse event. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26490?source=see_link\">",
"     \"Evaluation of the potential renal transplant recipient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33559?source=see_link\">",
"     \"Clinical manifestations and diagnosis of coronary heart disease in end-stage renal disease (dialysis)\"",
"    </a>",
"    .) Useful algorithms have been proposed for the cardiac evaluation of high-risk transplant candidates [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once the patient is placed on the transplant list after undergoing an initial cardiovascular evaluation,",
"    <strong>",
"     continued",
"    </strong>",
"    cardiovascular surveillance is required for many patients, particularly those deemed high-risk. In such patients, the cardiovascular status may deteriorate during the prolonged wait for a kidney. There is, however, no firm consensus as to who should be tested, at what interval, and with what modality. This decision is made in part by estimation of patient risk and by anticipation of the time to transplantation.",
"   </p>",
"   <p>",
"    A high-risk patient is defined as an individual with more than a 20 percent risk of a cardiovascular event in the next 10 years based upon the Framingham risk score. In comparison, patients with less than a 10 percent risk of a cardiovascular event in the next 10 years are considered to be at low risk.",
"   </p>",
"   <p>",
"    A review of how one estimates cardiovascular risk in an individual in the general population, including the Framingham risk score, and of the different noninvasive and invasive tests that may be utilized in this evaluation are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=see_link\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26490?source=see_link\">",
"     \"Evaluation of the potential renal transplant recipient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26584?source=see_link\">",
"     \"Myocardial dysfunction in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following represents general recommendations for the timing of reevaluations in patients on the transplant waiting list that were adopted by many transplant programs based upon a National Conference Report published in 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/4\">",
"     4",
"    </a>",
"    ]; these recommendations are consistent with the 2005",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines for coronary artery disease in dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the initial cardiac evaluation was negative for cardiac disease, then:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Annual reevaluation if the patient is diabetic.",
"     </li>",
"     <li>",
"      Every two-year reevaluation if the patient is high risk but not diabetic.",
"     </li>",
"     <li>",
"      Every three year reevaluation if the patient is low risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the initial cardiac evaluation was positive for cardiac disease, then:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Annual reevaluation if there was no history of a prior revascularization procedure or if there was a history of prior percutaneous coronary intervention.",
"     </li>",
"     <li>",
"      Every three year reevaluation then annual reevaluation for the patient who has had coronary artery bypass that successfully revascularized all target vessels. Annual reevaluation is recommended if the surgery was incomplete.",
"     </li>",
"     <li>",
"      Annual echocardiogram if there is asymptomatic moderate or worse aortic stenosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    clinical practice guidelines for cardiovascular disease in dialysis patients, as well as other",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines, can be accessed through the National Kidney Foundation's web site at",
"    <a class=\"external\" href=\"file://www.kidney.org/professionals/kdoqi/guidelines.cfm\">",
"     www.kidney.org/professionals/kdoqi/guidelines.cfm",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    This approach can be onerous and the recommendations were made before the kidney transplant waiting list was made more \"predictable.\" With the current allocation algorithm, it may be more practical to emphasize cardiac surveillance of those patients within the top two years of the top of the list.",
"   </p>",
"   <p>",
"    The recommendations from the 2003 National Conference were based on the use of noninvasive assessment of coronary heart disease because of the desire to avoid widespread use of coronary angiography. However, the utility of such noninvasive testing in patients with chronic kidney disease has been questioned because it is less reliable in detecting silent myocardial ischemia, and in predicting the occurrence of cardiac events post-transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In addition, the incidence of ischemic heart disease events in low-risk transplant candidates (&lt;10 percent coronary risk at 10 years) who are not screened appears to be very low [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result, surveillance cardiac testing in waitlisted patients based upon ongoing clinical assessment of cardiac risk rather than the recommended practice of periodic screening may result in fewer investigations without an associated increased frequency of cardiac events.",
"   </p>",
"   <p>",
"    For these reasons, the practitioner is advised to view current guidelines as recommendations rather than as strict rules and to combine them with clinical judgement. In addition, excessive reliance on noninvasive tests that are not sufficiently accurate to exclude significant coronary heart disease in high-risk candidates may engender a false sense of security [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Physical activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the benefits of increased physical activity on all-cause and cardiovascular mortality have been well established in the general population, prospective studies in patients with chronic kidney disease are lacking. However, mortality risks have been reported to be greatest for patients with severe limitations in either moderate or vigorous physical activity and lowest for patients who exercise regularly [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. These data support the view that patients should be encouraged to engage in frequent physical activity while waiting for a transplant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20136?source=see_link\">",
"     \"Physical activity in end-stage renal disease and renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Obesity and weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Morbid obesity may be a major concern in the evaluation of renal transplant candidates and those on the waiting list and patients are frequently requested or required to lose weight in order to be listed on the waitlist or maintain their active status. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26490?source=see_link\">",
"     \"Evaluation of the potential renal transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a growing body of evidence that, paradoxically, obesity might be beneficial for dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/32\">",
"     32",
"    </a>",
"    ] and that loss of weight in order to obtain a transplant might be detrimental to outcome. Much of the data supporting these contentions however, comes from database analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11240/abstract/33\">",
"     33",
"    </a>",
"    ] and specific recommendations for individual patients should be individualized. However, it should not be taken for granted that weight loss in obese transplant candidates will always be in their interest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/46/25315?source=see_link\">",
"       \"Patient information: Kidney transplant (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/15/12531?source=see_link\">",
"       \"Patient information: Planning for a kidney transplant (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The kidney transplant waiting list in the United States continues to grow, particularly with respect to the proportion of older individuals. Over the last decade, the proportion of older candidate groups aged over 50 years increased, while the proportion of younger candidates decreased. The ratio of Caucasian to African-American listed registrants has remained unchanged over the last decade. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Demographics'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      Patients currently remain on the waitlist for increasingly prolonged periods. This may in part reflect the increasing number of patients placed on the inactive list. The time to transplant varies by blood type, ethnic group, and panel reactive antibody levels. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Waiting time'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Overall mortality on the waiting list is approximately 6 percent per year, with a higher estimated rate for diabetics and older individuals. Much of the mortality is in patients who are on the inactive list. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Death on the waiting list'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Deceased donor transplantation requires access to the waiting list, which in turn requires access to a transplant center. A number of variables may inhibit timely referral to transplantation. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Access to the waiting list'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of the inclusion of histocompatibility matching in the allocation algorithm, the allocation of deceased donors is inherently unpredictable. However, changes in the kidney allocation algorithm over the last few years have somewhat alleviated this unpredictability. Further changes are anticipated. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Unpredictability of allocation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since patients on the active transplant list can be called for a transplant at any time, every effort must be made to optimize their health according to best practices and published clinical practice guidelines. There is widespread agreement that continued cardiovascular surveillance is required for many patients, particularly those deemed \"high-risk\" (greater than a 20 percent risk of a cardiovascular event in the next 10 years), since their cardiovascular status may deteriorate during the prolonged wait for a kidney. Patients should also be encouraged to engage in frequent physical activity while waiting for a transplant. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Health maintenance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/1\">",
"      Leichtman AB, Cohen D, Keith D, et al. Kidney and pancreas transplantation in the United States, 1997-2006: the HRSA Breakthrough Collaboratives and the 58 DSA Challenge. Am J Transplant 2008; 8:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/2\">",
"      Axelrod DA, McCullough KP, Brewer ED, et al. Kidney and pancreas transplantation in the United States, 1999-2008: the changing face of living donation. Am J Transplant 2010; 10:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/3\">",
"      Cohen DJ, St Martin L, Christensen LL, et al. Kidney and pancreas transplantation in the United States, 1995-2004. Am J Transplant 2006; 6:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/4\">",
"      Gaston RS, Danovitch GM, Adams PL, et al. The report of a national conference on the wait list for kidney transplantation. Am J Transplant 2003; 3:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/5\">",
"      Danovitch GM, Cohen DJ, Weir MR, et al. Current status of kidney and pancreas transplantation in the United States, 1994-2003. Am J Transplant 2005; 5:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/6\">",
"      Huang E, Poommipanit N, Sampaio MS, et al. Intermediate-term outcomes associated with kidney transplantation in recipients 80 years and older: an analysis of the OPTN/UNOS database. Transplantation 2010; 90:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/7\">",
"      Schaeffner ES, Rose C, Gill JS. Access to kidney transplantation among the elderly in the United States: a glass half full, not half empty. Clin J Am Soc Nephrol 2010; 5:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/8\">",
"      Bunnapradist S, Danovitch GM. Kidney transplants for the elderly: hope or hype? Clin J Am Soc Nephrol 2010; 5:1910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/9\">",
"      Schold J, Srinivas TR, Sehgal AR, Meier-Kriesche HU. Half of kidney transplant candidates who are older than 60 years now placed on the waiting list will die before receiving a deceased-donor transplant. Clin J Am Soc Nephrol 2009; 4:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/10\">",
"      Schold JD, Srinivas TR, Kayler LK, Meier-Kriesche HU. The overlapping risk profile between dialysis patients listed and not listed for renal transplantation. Am J Transplant 2008; 8:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/11\">",
"      Dudley CR, Johnson RJ, Thomas HL, et al. Factors that influence access to the national renal transplant waiting list. Transplantation 2009; 88:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/12\">",
"      Schold JD, Meier-Kriesche HU. Comparable barriers to access to kidney transplantation across national lines. Transplantation 2009; 88:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/13\">",
"      Meier-Kriesche HU, Ojo AO, Port FK, et al. Survival improvement among patients with end-stage renal disease: trends over time for transplant recipients and wait-listed patients. J Am Soc Nephrol 2001; 12:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/14\">",
"      Gill JS, Rose C, Pereira BJ, Tonelli M. The importance of transitions between dialysis and transplantation in the care of end-stage renal disease patients. Kidney Int 2007; 71:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/15\">",
"      Delmonico FL, McBride MA. Analysis of the wait list and deaths among candidates waiting for a kidney transplant. Transplantation 2008; 86:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/16\">",
"      Merion RM, Ashby VB, Wolfe RA, et al. Deceased-donor characteristics and the survival benefit of kidney transplantation. JAMA 2005; 294:2726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/17\">",
"      Pascual J, Zamora J, Pirsch JD. A systematic review of kidney transplantation from expanded criteria donors. Am J Kidney Dis 2008; 52:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/18\">",
"      Schold JD, Meier-Kriesche HU. Which renal transplant candidates should accept marginal kidneys in exchange for a shorter waiting time on dialysis? Clin J Am Soc Nephrol 2006; 1:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/19\">",
"      Molnar MZ, Streja E, Kovesdy CP, et al. Age and the associations of living donor and expanded criteria donor kidneys with kidney transplant outcomes. Am J Kidney Dis 2012; 59:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/20\">",
"      Mezrich JD, Pirsch JD, Fernandez LA, et al. Differential outcomes of expanded-criteria donor renal allografts according to recipient age. Clin J Am Soc Nephrol 2012; 7:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/21\">",
"      Winkelmayer WC, Mehta J, Chandraker A, et al. Predialysis nephrologist care and access to kidney transplantation in the United States. Am J Transplant 2007; 7:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/22\">",
"      Danovitch GM, Cecka JM. Allocation of deceased donor kidneys: past, present, and future. Am J Kidney Dis 2003; 42:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/23\">",
"      Leichtman, A, Stegall, M. A dynamic period of reappraisal and innovation in kidney transplantation practice and policies. NephSAP 2008; 7:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/24\">",
"      Pilmore H. Cardiac assessment for renal transplantation. Am J Transplant 2006; 6:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/25\">",
"      K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/26\">",
"      Ohtake T, Kobayashi S, Moriya H, et al. High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination. J Am Soc Nephrol 2005; 16:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/27\">",
"      Gill JS, Ma I, Landsberg D, et al. Cardiovascular events and investigation in patients who are awaiting cadaveric kidney transplantation. J Am Soc Nephrol 2005; 16:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/28\">",
"      Kasiske BL, Malik MA, Herzog CA. Risk-stratified screening for ischemic heart disease in kidney transplant candidates. Transplantation 2005; 80:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/29\">",
"      Fishbane S. Cardiovascular risk evaluation before kidney transplantation. J Am Soc Nephrol 2005; 16:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/30\">",
"      Stack AG, Martin DR. Association of patient autonomy with increased transplantation and survival among new dialysis patients in the United States. Am J Kidney Dis 2005; 45:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/31\">",
"      Kutner NG, Zhang R, Bowles T, Painter P. Pretransplant physical functioning and kidney patients' risk for posttransplantation hospitalization/death: evidence from a national cohort. Clin J Am Soc Nephrol 2006; 1:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/32\">",
"      Ikizler TA. Resolved: being fat is good for dialysis patients: the Godzilla effect: pro. J Am Soc Nephrol 2008; 19:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11240/abstract/33\">",
"      Schold JD, Srinivas TR, Guerra G, et al. A \"weight-listing\" paradox for candidates of renal transplantation? Am J Transplant 2007; 7:550.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7333 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-4327E6E395-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_62_11240=[""].join("\n");
var outline_f10_62_11240=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THE ACTIVE AND INACTIVE LIST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DEMOGRAPHICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ethnicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Gender and blood group",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Renal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      LISTING PRACTICES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      WAITING TIME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Previously transplanted and presensitized patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DEATH ON THE WAITING LIST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Expanded donor kidneys",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ACCESS TO THE WAITING LIST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      UNPREDICTABILITY OF ALLOCATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      HEALTH MAINTENANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Preventive health measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cardiovascular testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Physical activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Obesity and weight loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33559?source=related_link\">",
"      Clinical manifestations and diagnosis of coronary heart disease in end-stage renal disease (dialysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11224?source=related_link\">",
"      Dialysis issues prior to and after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=related_link\">",
"      Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30697?source=related_link\">",
"      Evaluation of the living kidney donor and risk of donor nephrectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26490?source=related_link\">",
"      Evaluation of the potential renal transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34570?source=related_link\">",
"      HLA and ABO sensitization and desensitization in renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26584?source=related_link\">",
"      Myocardial dysfunction in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/7/5240?source=related_link\">",
"      Organ sharing in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/46/25315?source=related_link\">",
"      Patient information: Kidney transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/15/12531?source=related_link\">",
"      Patient information: Planning for a kidney transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17992?source=related_link\">",
"      Patient survival after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20136?source=related_link\">",
"      Physical activity in end-stage renal disease and renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/29/43480?source=related_link\">",
"      Renal transplantation and the elderly patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_62_11241="Pregnancy in women with underlying renal disease";
var content_f10_62_11241=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pregnancy in women with underlying renal disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/62/11241/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/62/11241/contributors\">",
"     Phyllis August, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/62/11241/contributors\">",
"     John Vella, MD, FACP, FRCP, FASN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/62/11241/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/62/11241/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/62/11241/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/62/11241/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/62/11241/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/62/11241/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two questions that need to be addressed when a woman with underlying kidney disease becomes pregnant:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      What is the effect of pregnancy on the kidney disease?",
"     </li>",
"     <li>",
"      What is the effect of the kidney disease on pregnancy?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A review of issues relating to pregnancy in women with diabetic nephropathy is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36281?source=see_link\">",
"     \"Pregnancy risks in women with type 1 and type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42487?source=see_link\">",
"     \"Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/19/21816?source=see_link\">",
"     \"Pregnancy in women with diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFECT OF PREGNANCY ON KIDNEY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;When considering the effect of pregnancy on kidney disease, it is important to distinguish between changes in clinical manifestations and possible alterations in the long-term course of the disease. As an example, the degree of proteinuria increases in about one-half of cases and hypertension develops or worsens in about one-quarter of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]; severe hypertension can occur, potentially leading to maternal injury, premature delivery, or poor fetal outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/7\">",
"     7",
"    </a>",
"    ]. Marked worsening of edema also can be seen in women with the nephrotic syndrome. These changes generally resolve after delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Effect on renal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal function may decline as a result of pregnancy among patients with renal disease, determined in part by the severity of underlying renal disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnancy is associated with a permanent decline in renal function in between 0 and 10 percent of women when the glomerular filtration rate is initially normal or only mildly reduced (plasma creatinine concentration less than 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or 132",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/2-4,7\">",
"       2-4,7",
"      </a>",
"      ]. Other patients may experience a transient decline in renal function during pregnancy. One study, for example, evaluated 360 women with chronic glomerulonephritis and normal renal function: 171 became pregnant while the remainder did not conceive [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/4\">",
"       4",
"      </a>",
"      ]. After follow-up for as long as 30 years, there was no difference in renal survival between the two groups. Patients with hypertension were much more likely to develop progressive disease independent of pregnancy status.",
"     </li>",
"     <li>",
"      The outcome may be different in women with moderate renal insufficiency (plasma creatinine concentration between 1.5 and 2.9",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or 132 and 255",
"      <span class=\"nowrap\">",
"       &micro;mol/L).",
"      </span>",
"      In this setting, the plasma creatinine concentration tends to decline modestly during the first half of pregnancy (as it does in women without kidney disease, who have as much as a 50 percent increase in glomerular filtration rate) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/8\">",
"       8",
"      </a>",
"      ] and then may rise above the previous baseline as the pregnancy progresses [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=see_link\">",
"       \"Renal and urinary tract physiology in normal pregnancy\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      One study, for example, evaluated 76 pregnant women with an initial mean plasma creatinine concentration of 1.9",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (168",
"      <span class=\"nowrap\">",
"       &micro;mol/L);",
"      </span>",
"      the creatinine concentration increased to a mean of 2.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (223",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"      by the third trimester [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/11\">",
"       11",
"      </a>",
"      ]. Among those with an initial value between 1.4 and 1.9",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (124 and 168",
"      <span class=\"nowrap\">",
"       &micro;mol/L),",
"      </span>",
"      the risk of a decline in kidney function was approximately 40 percent. Women with chronic kidney disease may experience an irreversible decline in glomerular filtration rate that is greater than predicted based upon the patient's previous course. Several small studies suggest that as many as one-third experience an irreversible decline [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/7,9,12\">",
"       7,9,12",
"      </a>",
"      ] and, in the previously mentioned study of 76 women, 10 percent progressed to end-stage renal disease by 12 months post partum; among 8 patients, 7 had a decline in renal function during pregnancy and 1 had stable renal function before and immediately after pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/11\">",
"       11",
"      </a>",
"      ]. The risk of acceleration was highest (33 versus 2 percent) among those with an initial plasma creatinine concentration above 2.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (177",
"      <span class=\"nowrap\">",
"       &micro;mol/L).",
"      </span>",
"      The risk of an irreversible loss of GFR may exceed 50 percent in patients who also have uncontrolled hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The issues are somewhat different in women with a baseline plasma creatinine concentration above 3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (265",
"      <span class=\"nowrap\">",
"       &micro;mol/L).",
"      </span>",
"      These women frequently have amenorrhea or anovulatory menstrual cycles. Thus, the likelihood of conception and then carrying the fetus to term is low; however, contraception is advisable because of poor pregnancy outcomes with advanced CKD. [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/2,7\">",
"       2,7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36484?source=see_link\">",
"       \"Reproductive and sexual dysfunction in uremic women\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, an elevated plasma creatinine concentration (above 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 132",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    and hypertension are the major risk factors for permanent exacerbation of underlying renal disease. It has been proposed that the type of disease also may be important as accelerated progression may be more likely in membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and reflux nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/3,13,14\">",
"     3,13,14",
"    </a>",
"    ]. However, most investigators have found that etiology (other than lupus nephritis) is probably not a major determinant of worsening renal disease if factored for preexistent renal insufficiency and hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/12,13,15\">",
"     12,13,15",
"    </a>",
"    ]. Women with vesicoureteral reflux may be at increased risk for urinary tract infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Lupus nephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The negative prognostic implications of preexisting hypertension and azotemia in pregnancy discussed above also apply to lupus patients. The general complications and management of pregnancy in women with systemic lupus erythematosus are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/45/39641?source=see_link\">",
"     \"Pregnancy in women with systemic lupus erythematosus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of active lupus nephritis in the postpartum period is similar to that in other patients with this disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=see_link\">",
"     \"Therapy of diffuse or focal proliferative lupus nephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Kidney biopsy during pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are few indications for kidney biopsy during pregnancy, this procedure can be performed safely by experienced operators in women with well-controlled blood pressure and normal coagulation indices [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/16\">",
"     16",
"    </a>",
"    ]. It has been suggested that a biopsy may be performed if there is a sudden unexplained deterioration in renal function or markedly symptomatic nephrotic syndrome occurring before 32 weeks gestation. Biopsy after week 32 is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EFFECT OF KIDNEY DISEASE ON PREGNANCY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pregnancy in mild to moderate CKD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of preexistent renal disease on the course of pregnancy is somewhat better established. The rate of live births is above 90 percent in women with normal renal function and lower with modest CKD as long as the blood pressure is well controlled [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/2,6,7,12,15,17\">",
"     2,6,7,12,15,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are, however, some major risks of kidney disease in pregnancy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CKD is associated with higher rates of adverse maternal outcomes. The best data come from a meta-analysis of 13 cohort studies in which pregnant women with preexisting renal impairment were significantly more likely to develop gestational hypertension, preeclampsia, eclampsia, or to die (12 versus 2 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/18\">",
"       18",
"      </a>",
"      ]. Maternal mortality was more frequent in those with CKD (4 versus 1 percent), although this was not statistically significant.",
"      <br/>",
"      <br/>",
"      Preeclampsia may be more difficult to diagnose in women with CKD who already have hypertension and proteinuria. However, features of the preeclamptic syndrome may include significant worsening of hypertension and proteinuria, in association with a decreased platelet count or increased liver enzymes. Although this syndrome generally occurs in the third trimester, women with underlying renal disease are at greater risk for second trimester preeclampsia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link\">",
"       \"Preeclampsia: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fetal outcomes are also worse in women with CKD [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/7,11,15,18-20\">",
"       7,11,15,18-20",
"      </a>",
"      ]. In the meta-analysis just mentioned, the frequency of premature birth was significantly higher among women with renal impairment (13 versus 6 percent), while nonsignificantly higher rates were noted for intrauterine growth restriction (5 versus 0 percent), small for gestational age (14 versus 8 percent), and stillbirth (5 versus 2 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/18\">",
"       18",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Fetal survival is lower when hypertension is uncontrolled [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/7,15,19\">",
"       7,15,19",
"      </a>",
"      ]. The relative risk of fetal death has been estimated by Jungers and Chauveau to be approximately tenfold higher in women with a mean arterial pressure of greater than 105 mmHg at conception compared to those with spontaneous or therapeutically-achieved normotension [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate issue from the effect on kidney disease on pregnancy is the possible effects of drugs used to treat kidney disease on the fetus if pregnancy occurs. Angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and some immunosuppressive drugs (particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ) should be discontinued at the earliest indication of pregnancy. In addition, women who are not pregnant but are of child-bearing age should be warned about the potential consequences of these agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pregnancy in the dialysis patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of pregnancy may be difficult in women with end-stage renal disease, particularly because serum levels of beta-human chorionic gonadotropin (beta-hCG) may be increased in the absence of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/1\">",
"     1",
"    </a>",
"    ]. Among women suspected of being pregnant who have elevated serum beta-hCG, ultrasonography should be performed to verify the presence of a viable fetus and to obtain the approximate gestational age.",
"   </p>",
"   <p>",
"    The reported frequency of conception among women of child-bearing age on dialysis ranges from 0.3 to 1.5 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/1\">",
"     1",
"    </a>",
"    ]. Although fetal wastage is markedly increased when pregnancy occurs, improvements in management have resulted in an enhanced frequency of live births (40 to 75 percent of all pregnancies) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/19,21-29\">",
"     19,21-29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one survey of 1281 women of childbearing age undergoing maintenance dialysis, for example, 1.5 percent became pregnant in a two year period; since 1990, 52 percent of these pregnancies resulted in surviving infants, a much better result than in earlier years [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two other large surveys in Belgium (1472 women of childbearing age) and United States dialysis clinics (6230 women) noted successful outcomes in 50 and 40 percent of pregnancies, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. The outcomes were similar in patients treated with hemodialysis and peritoneal dialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The apparent improvement in outcome is thought to reflect more aggressive management of the uremic state in women with end-stage renal disease who become pregnant [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/29\">",
"     29",
"    </a>",
"    ]. Summary recommendations have been published concerning the optimal management of such patients (",
"    <a class=\"graphic graphic_table graphicRef58352 \" href=\"UTD.htm?25/13/25820\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/19,24,30,31\">",
"     19,24,30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several major components of this regimen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      More intensive dialysis with the BUN being maintained at under 50",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (17",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      or even under 45",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (16",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/19,24,29,32,33\">",
"       19,24,29,32,33",
"      </a>",
"      ]. In clinical practice, this is usually achieved by increasing the frequency of dialysis (eg, increase to 4 to 6",
"      <span class=\"nowrap\">",
"       sessions/week)",
"      </span>",
"      or switching to long nightly dialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/29\">",
"       29",
"      </a>",
"      ]. Ameliorating the uremic milieu can avoid polyhydramnios, help control hypertension, increase birth weight and gestational age, and improve maternal nutrition.",
"     </li>",
"     <li>",
"      Pregnant women often require higher doses of erythropoietin to maintain an adequate red cell mass (hemoglobin of 10 to 11",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      since the physiologic changes and demands of pregnancy may result in worsening of anemia.",
"     </li>",
"     <li>",
"      Metabolic acidosis and hypocalcemia should be corrected.",
"     </li>",
"     <li>",
"      Careful uterine and fetal monitoring during hemodialysis, such as assessment of the fetal heart rate (particularly during the last portion of a session), combined with measures aimed at preventing dialysis-induced hypotension should be performed. Maternal hemodynamic instability may compromise the uteroplacental circulation and may be associated with the induction of uterine contractions [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Attention to nutritional considerations and proper weight gain are essential for a successful pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/30\">",
"     30",
"    </a>",
"    ]. Although the recommended weight gain in the second and third trimesters is between 0.3 to 0.5 kg per week, it is difficult to distinguish excess fluid gained between dialysis sessions from that due to pregnancy associated weight gain. Given that the pregnant dialysis patient should undergo dialysis five to seven days per week, the clinician should perform a careful weekly physical examination to help detect the presence of excess fluid unrelated to the pregnancy.",
"   </p>",
"   <p>",
"    Despite optimal therapy, mothers are at increased risk for severe hypertension, and prematurity still occurs in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/22,27\">",
"     22,27",
"    </a>",
"    ]. In a review of 120 pregnant dialysis patients, the mean gestational age at delivery was only 30.5 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/27\">",
"     27",
"    </a>",
"    ]. Preeclampsia is the greatest risk factor for prematurity and other adverse outcomes. In a single-center series of 52 patients, preeclampsia was associated with a lower successful delivery rate (60 versus 92.9 percent), extremely premature delivery rate (77.8 versus 3.3), and lower gestational age and birth weight compared to those without preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, it may be advantageous to delay pregnancy among hemodialysis patients in whom future renal transplantation is likely since, compared to the dialysis patient, transplant recipients have a higher incidence of successful pregnancies and fewer complications and birth abnormalities (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pregnancy in the renal transplant recipient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fertility generally returns after renal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/32,36-39\">",
"     32,36-39",
"    </a>",
"    ]. However, the rates of both pregnancy and successful pregnancy (ie, resulting in a live birth) remain far lower than in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. The best data come from a longitudinal cohort of 30,078 female transplant recipients aged 15 to 45 years [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During the first three posttransplant years, the unadjusted pregnancy rate was 33 per 1000 women compared with more than 100 per 1000 women in the general population. There was also a temporal trend toward reduced pregnancy rates over time, ranging from 59 per 1000 women in 1990 to 19 per 1000 women in 2003.",
"     </li>",
"     <li>",
"      In transplant recipients, 55 percent of pregnancies resulted in a live birth compared with nearly 70 percent in the general population. Although the proportion of successful pregnancies remained relatively constant between 1990 and 2003, the reasons for fetal loss change over time. The unadjusted rate of therapeutic abortions declined from 19 to 6 percent, while fetal loss due to other causes increased from 25 to 37 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to an increased risk of fetal loss, the frequency of preeclampsia, intrauterine growth restriction, and premature delivery are elevated in transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/38-42\">",
"     38-42",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a meta-analysis that included 4706 pregnancies in 3570 kidney transplant recipients, preeclampsia, gestational diabetes, and preterm delivery occurred in 27, 8, and 46 percent of patients, respectively, compared with approximately 4, 4, and 13 percent in the general United States population [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Of 105 pregnancies in 101 transplant recipients who were identified through the United Kingdom (UK) Obstetric Surveillance System, 52 percent delivered at &lt;37 weeks, compared with the national rate in the UK of 8 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/42\">",
"       42",
"      </a>",
"      ]. Twenty four percent of infants were small for gestational age (defined as &lt;10",
"      <sup>",
"       th",
"      </sup>",
"      percentile). Preeclampsia developed in 24 percent of transplant recipients compared with 4 percent in a comparison group (women who delivered in the same hospital around the same time as the transplant recipient). There was no increase in gestational diabetes among transplant recipients compared with the comparison group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pregnancy usually has no important early effect on renal function in this setting and is limited by the same factors described above in women with any underlying renal disease &mdash; a plasma creatinine concentration above 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (132",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    and hypertension that cannot be easily controlled [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/32,37,43\">",
"     32,37,43",
"    </a>",
"    ]. In the study from the UK that is cited above, a poor pregnancy outcome was predicted by &gt;1 previous kidney transplants, first trimester serum creatinine &gt;1.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (125",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    and diastolic blood pressure &gt;90 mmHg in the second and third trimesters [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long-term effect of pregnancy on renal function is less clear. Data are largely based on retrospective small studies, with somewhat conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. In one of the largest best-designed studies, the long-term outcomes of 39 women who became pregnant with a functioning allograft were each compared with three matched control patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/45\">",
"     45",
"    </a>",
"    ]. At the end of follow-up of 15 years, allograft and patient survival were similar in both groups (72 and 85 percent in pregnant women versus 69 and 79 percent in the control group, respectively). In addition, kidney function was similar at 1, 5, and 10 years post-transplant. This suggests that pregnancy does not have long-term adverse effects on survival of either the allograft or patient.",
"   </p>",
"   <p>",
"    Women are usually advised to wait at least one year after living related donor transplantation and two years after deceased transplantation to avoid complications arising from immunotherapy and rejection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    .) In addition, the renal allograft should be functioning well, with a stable serum creatinine level of less than 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (132",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    and urinary protein excretion less than 500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/37\">",
"     37",
"    </a>",
"    ]. Although not recommended, women who become pregnant in the first 6 to 12 months posttransplantation are also likely to have a successful pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vaginal delivery should not be impaired, as the pelvic allograft does not obstruct the birth canal in most patients. The obstetrician should review operative notes from the transplant procedure to confirm location of the allograft and ureter. A renal ultrasound might also aid in precise location. This information should be placed in the prenatal record to guide the surgeon if a Cesarean delivery is performed. Prophylactic antibiotics and careful wound closure are warranted to avoid complications in these immunocompromised patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    is not established in pregnancy. Hypertension can be induced or exacerbated (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    ) and some clinicians have suggested that the dose be limited to 2 to 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/46\">",
"     46",
"    </a>",
"    ]. Cyclosporine does not appear to be a major teratogen, as suggested by the results of a meta-analysis of 15 studies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    metabolism appears to be increased during pregnancy and higher doses may be required to maintain plasma levels in the therapeutic range [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/36\">",
"     36",
"    </a>",
"    ]. There is no consensus regarding whether or not cyclosporine doses should be increased in pregnant women whose levels are subtherapeutic. In women several years post-transplant with stable renal function, our approach is to continue the prepregnancy dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects on fetal development have been reported in laboratory animals with doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF) lower than those used in clinical practice. MMF is listed as a category D drug (positive evidence of risk) for use in pregnancy by the FDA due to increases in both first trimester pregnancy loss and congenital malformations, including cleft lip and palate, and anomalies of the distal limbs, heart, esophagus, and kidneys (",
"    <a class=\"graphic graphic_table graphicRef54317 \" href=\"UTD.htm?30/57/31644\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar findings have been noted in kidney transplant recipients. The magnitude of risk was illustrated in a series of 18 kidney transplant recipients and 26 pregnancies with exposure to MMF [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/48\">",
"     48",
"    </a>",
"    ]. There were 11 spontaneous abortions and 15 live births. In addition, 4 of the 15 children had structural malformations: hypoplastic nails and shortened fifth finger, microtia with cleft lip and palate, microtia alone, and neonatal death with multiple malformations.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    is",
"    <strong>",
"     contraindicated",
"    </strong>",
"    in pregnancy. As a result, females of childbearing potential should have a negative pregnancy test within one week prior to beginning therapy. Two reliable forms of contraception should be used beginning four weeks prior to, during, and for six weeks after therapy. We recommend that kidney transplant recipients who wish to conceive should change from MMF to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , if there are no contraindications to the switch. MMF should be discontinued at least six weeks prior to attempted conception [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?21/56/22406?source=see_link\">",
"     \"Mycophenolate: Patient drug information\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Sirolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    (Rapamycin) is",
"    <strong>",
"     contraindicated",
"    </strong>",
"    in pregnancy as animal studies have demonstrated embryotoxicity and fetotoxicity with increased mortality, reduced fetal weights and delayed ossification. However, there are no adequate and well-controlled studies in pregnant women. There is also evidence in rats that rapamycin may block pregnancy-related myometrial cell proliferation, a key element in the maintenance of uterine quiescence [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/49\">",
"     49",
"    </a>",
"    ]. In Drosophila and mice, rapamycin promotes fetal oocyte atresia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    macrophage phagocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/50\">",
"     50",
"    </a>",
"    ]. Its use should also be discontinued at least 12 weeks prior to attempted conception [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?26/35/27190?source=see_link\">",
"     \"Sirolimus: Patient drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, we recommend that women post-transplant who wish to conceive be switched prior to conception from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . Upon delivery, it is our practice to switch the mother back to her basal immunosuppression in view of the potential benefits of the newer agents to prevent late acute rejection and chronic allograft nephropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a paucity of data concerning the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    on pregnancy. Among 100 pregnancies in 84 women treated with tacrolimus, of whom 27 percent were renal transplant recipients, 68 progressed to a live birth, with 60 percent of deliveries being premature [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/52\">",
"     52",
"    </a>",
"    ]. There were four babies with malformations, but no consistent pattern of anatomic abnormality.",
"   </p>",
"   <p>",
"    As with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    require frequent monitoring of renal function and drug levels. During pregnancy, the hepatic cytochrome P450 enzymes may be inhibited, which can lead to increased serum levels of tacrolimus. The dose may therefore have to be significantly reduced to prevent toxicity (sometimes by as much as 60 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Male fertility after transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressive agents used in renal transplantation may affect male fertility. Although numerous reports have indicated that male transplant recipients can successfully father healthy offspring [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/53\">",
"     53",
"    </a>",
"    ], one report suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    may cause impaired spermatogenesis and reduce male fertility [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/54\">",
"     54",
"    </a>",
"    ]. This is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17562?source=see_link&amp;anchor=H29#H29\">",
"     \"Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation\", section on 'Teratogenicity/effects in pregnancy and fertility'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Evaluation of renal dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of renal dysfunction and the evaluation of the pregnant allograft recipient are similar to that in the nonpregnant transplant patient. Additional concerns include the causes of renal dysfunction unique to pregnancy as well as the interplay between pregnancy and the presence of a renal allograft [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2072?source=see_link\">",
"     \"Differential diagnosis of renal allograft dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33479?source=see_link\">",
"     \"Acute kidney injury (acute renal failure) in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although women are advised to wait a sufficient period of time after transplantation to become pregnant, episodes of acute rejection are not uncommon during pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11241/abstract/1,40\">",
"       1,40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Obstruction of the transplant ureter by the uterus, although unusual, has been reported.",
"     </li>",
"     <li>",
"      Severe preeclampsia and TTP-HUS (due to pregnancy) may be difficult to distinguish in the pregnant transplant patient, particularly since they both present with hemolysis and thrombocytopenia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33479?source=see_link\">",
"       \"Acute kidney injury (acute renal failure) in pregnancy\"",
"      </a>",
"      .) Although a TTP-HUS-like picture may also be observed in transplant patients with hyperacute rejection or in those administered OKT3 or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , these clinical settings occur immediately or soon after transplantation and are therefore unlikely to be observed in a pregnant patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     OBSTETRICAL MANAGEMENT OF WOMEN WITH UNDERLYING RENAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with renal disease should be monitored jointly by a nephrologist and by an obstetrician familiar with the effects of renal disease on pregnancy. General principles of management include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased frequency of prenatal visits; these should occur every two weeks until the third trimester and then weekly.",
"     </li>",
"     <li>",
"      Early detection and treatment of asymptomatic bacteriuria.",
"     </li>",
"     <li>",
"      Serial monitoring (at least monthly) of maternal renal function.",
"     </li>",
"     <li>",
"      Close monitoring for the development of preeclampsia.",
"     </li>",
"     <li>",
"      Fetal surveillance with ultrasound and fetal heart rate monitoring to assess fetal growth and well-being.",
"     </li>",
"     <li>",
"      Aggressive treatment of maternal hypertension. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link\">",
"       \"Management of hypertension in pregnant and postpartum women\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Preterm intervention may be necessary in the presence of deteriorating renal function, severe preeclampsia, fetal growth restriction, or nonreassuring fetal testing (eg, fetal distress). In most women, elective delivery is indicated if labor has not occurred by the estimated date of confinement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/42/36518?source=see_link\">",
"       \"Patient information: Systemic lupus erythematosus and pregnancy (Beyond the Basics)\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H142691\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal function may decline as a result of pregnancy among patients with renal disease. Increased risk for this decline is conferred by an elevated plasma creatinine concentration (above 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or 132",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"      and hypertension. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Effect on renal function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal biopsy can be performed safely in women with well-controlled blood pressure and normal coagulation indices who are at or before 32 weeks gestation. Biopsy after week 32 is not recommended. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Kidney biopsy during pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal impairment is associated with both increased risk for adverse maternal outcomes, including gestational hypertension, preeclampsia, eclampsia, and death, and also adverse fetal outcomes, including premature birth, intrauterine growth restriction, small for gestational age, and still birth. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pregnancy in mild to moderate CKD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The reported frequency of conception among women of child-bearing age on dialysis ranges from 0.3 to 1.5 percent per year. Aggressive management of the uremic state has increased the number of live births. Supportive measures include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Intensive dialysis targeting a BUN under 50",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (17",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      or even under 45",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (16",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      Target hemoglobin of 10 to 11",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"     </li>",
"     <li>",
"      Correction of metabolic acidosis and hypocalcemia.",
"     </li>",
"     <li>",
"      Careful uterine and fetal monitoring during hemodialysis combined with measures to prevent dialysis-induced hypotension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attention to nutrition and proper weight gain, including a careful weekly physical examination to help detect volume overload unrelated to the pregnancy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Pregnancy in the dialysis patient'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fertility improves after renal transplantation. However, pregnancy and live birth rates are far lower in female transplant recipients than in the general population. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pregnancy in the renal transplant recipient'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnancy has little or no effect on renal function in the transplant patient. Women are advised to wait at least one year after living related donor transplantation and two years after deceased transplantation to avoid complications arising from immunotherapy and rejection. The renal allograft should be functioning well, with a stable serum creatinine level of less than 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (133",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"      and urinary protein excretion less than 500",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pregnancy in the renal transplant recipient'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunosuppressive regimens may need to be adjusted prior to attempting to conceive.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       Mycophenolate",
"      </a>",
"      mofetil (MMF) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      are contraindicated in pregnancy. Women should change from MMF to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , and from sirolimus to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , if there are no contraindications to the switch. Upon delivery, it is our practice to switch the mother back to her basal immunosuppression to prevent late acute rejection and chronic allograft nephropathy. Patients taking cyclosporine or tacrolimus require more frequent monitoring of renal function and drug levels during pregnancy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pregnancy in the renal transplant recipient'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with renal disease should be monitored jointly by a nephrologist and by an obstetrician familiar with the effects of renal disease on pregnancy. General principles of management include increased frequency of prenatal visits; early detection and treatment of asymptomatic bacteriuria; serial monitoring of maternal renal function and for the treatment of hypertension; monitoring for the development of preeclampsia; and fetal surveillance with ultrasound and fetal heart rate. Preterm intervention may be necessitated by deteriorating renal function, severe preeclampsia, fetal growth restriction, or nonreassuring fetal testing. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Obstetrical management of women with underlying renal disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/1\">",
"      Hou S. Pregnancy in chronic renal insufficiency and end-stage renal disease. Am J Kidney Dis 1999; 33:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/2\">",
"      Hayslett JP. Interaction of renal disease and pregnancy. Kidney Int 1984; 25:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/3\">",
"      Surian M, Imbasciati E, Cosci P, et al. Glomerular disease and pregnancy. A study of 123 pregnancies in patients with primary and secondary glomerular diseases. Nephron 1984; 36:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/4\">",
"      Jungers P, Houillier P, Forget D, et al. Influence of pregnancy on the course of primary chronic glomerulonephritis. Lancet 1995; 346:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/5\">",
"      Bar J, Ben-Rafael Z, Padoa A, et al. Prediction of pregnancy outcome in subgroups of women with renal disease. Clin Nephrol 2000; 53:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/6\">",
"      Rouse DJ, MacPherson C, Landon M, et al. Blood transfusion and cesarean delivery. Obstet Gynecol 2006; 108:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/7\">",
"      Hou S. Pregnancy in women with chronic renal disease. N Engl J Med 1985; 312:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/8\">",
"      Davison JM, Dunlop W. Renal hemodynamics and tubular function normal human pregnancy. Kidney Int 1980; 18:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/9\">",
"      Imbasciati E, Pardi G, Capetta P, et al. Pregnancy in women with chronic renal failure. Am J Nephrol 1986; 6:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/10\">",
"      Imbasciati E, Gregorini G, Cabiddu G, et al. Pregnancy in CKD stages 3 to 5: fetal and maternal outcomes. Am J Kidney Dis 2007; 49:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/11\">",
"      Jones DC, Hayslett JP. Outcome of pregnancy in women with moderate or severe renal insufficiency. N Engl J Med 1996; 335:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/12\">",
"      Jungers P, Houillier P, Forget D, Henry-Amar M. Specific controversies concerning the natural history of renal disease in pregnancy. Am J Kidney Dis 1991; 17:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/13\">",
"      Katz AI, Lindheimer MD. Does pregnancy aggravate primary glomerular disease? Am J Kidney Dis 1985; 6:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/14\">",
"      Packham DK, North RA, Fairley KF, et al. Pregnancy in women with primary focal and segmental hyalinosis and sclerosis. Clin Nephrol 1988; 29:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/15\">",
"      Packham DK, North RA, Fairley KF, et al. Primary glomerulonephritis and pregnancy. Q J Med 1989; 71:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/16\">",
"      Lindheimer MD, Davison JM. Renal biopsy during pregnancy: 'to b . . . or not to b . . .?'. Br J Obstet Gynaecol 1987; 94:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/17\">",
"      Fischer MJ, Lehnerz SD, Hebert JR, Parikh CR. Kidney disease is an independent risk factor for adverse fetal and maternal outcomes in pregnancy. Am J Kidney Dis 2004; 43:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/18\">",
"      Nevis IF, Reitsma A, Dominic A, et al. Pregnancy outcomes in women with chronic kidney disease: a systematic review. Clin J Am Soc Nephrol 2011; 6:2587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/19\">",
"      Jungers P, Chauveau D. Pregnancy in renal disease. Kidney Int 1997; 52:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/20\">",
"      Epstein FH. Pregnancy and renal disease. N Engl J Med 1996; 335:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/21\">",
"      Cunningham FG, Cox SM, Harstad TW, et al. Chronic renal disease and pregnancy outcome. Am J Obstet Gynecol 1990; 163:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/22\">",
"      Hou SH. Frequency and outcome of pregnancy in women on dialysis. Am J Kidney Dis 1994; 23:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/23\">",
"      Gadallah MF, Ahmad B, Karubian F, Campese VM. Pregnancy in patients on chronic ambulatory peritoneal dialysis. Am J Kidney Dis 1992; 20:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/24\">",
"      Hou SH. Pregnancy in women on haemodialysis and peritoneal dialysis. Baillieres Clin Obstet Gynaecol 1994; 8:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/25\">",
"      Bagon JA, Vernaeve H, De Muylder X, et al. Pregnancy and dialysis. Am J Kidney Dis 1998; 31:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/26\">",
"      Okundaye I, Abrinko P, Hou S. Registry of pregnancy in dialysis patients. Am J Kidney Dis 1998; 31:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/27\">",
"      Giatras I, Levy DP, Malone FD, et al. Pregnancy during dialysis: case report and management guidelines. Nephrol Dial Transplant 1998; 13:3266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/28\">",
"      Toma H, Tanabe K, Tokumoto T, et al. Pregnancy in women receiving renal dialysis or transplantation in Japan: a nationwide survey. Nephrol Dial Transplant 1999; 14:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/29\">",
"      Piccoli GB, Conijn A, Consiglio V, et al. Pregnancy in dialysis patients: is the evidence strong enough to lead us to change our counseling policy? Clin J Am Soc Nephrol 2010; 5:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/30\">",
"      Hou S. Modification of dialysis regimens for pregnancy. Int J Artif Organs 2002; 25:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/31\">",
"      Hou S. Pregnancy in dialysis patients: where do we go from here? Semin Dial 2003; 16:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/32\">",
"      Davison JM. Dialysis, transplantation, and pregnancy. Am J Kidney Dis 1991; 17:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/33\">",
"      Asamiya Y, Otsubo S, Matsuda Y, et al. The importance of low blood urea nitrogen levels in pregnant patients undergoing hemodialysis to optimize birth weight and gestational age. Kidney Int 2009; 75:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/34\">",
"      Luders C, Castro MC, Titan SM, et al. Obstetric outcome in pregnant women on long-term dialysis: a case series. Am J Kidney Dis 2010; 56:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/35\">",
"      Hull AR. More dialysis appears beneficial for pregnant ESRD patients (at least in Belgium). Am J Kidney Dis 1998; 31:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/36\">",
"      Muirhead N, Sabharwal AR, Rieder MJ, et al. The outcome of pregnancy following renal transplantation--the experience of a single center. Transplantation 1992; 54:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/37\">",
"      McKay DB, Josephson MA. Pregnancy in recipients of solid organs--effects on mother and child. N Engl J Med 2006; 354:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/38\">",
"      Gill JS, Zalunardo N, Rose C, Tonelli M. The pregnancy rate and live birth rate in kidney transplant recipients. Am J Transplant 2009; 9:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/39\">",
"      Levidiotis V, Chang S, McDonald S. Pregnancy and maternal outcomes among kidney transplant recipients. J Am Soc Nephrol 2009; 20:2433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/40\">",
"      McKay DB, Josephson MA, Armenti VT, et al. Reproduction and transplantation: report on the AST Consensus Conference on Reproductive Issues and Transplantation. Am J Transplant 2005; 5:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/41\">",
"      Deshpande NA, James NT, Kucirka LM, et al. Pregnancy outcomes in kidney transplant recipients: a systematic review and meta-analysis. Am J Transplant 2011; 11:2388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/42\">",
"      Bramham K, Nelson-Piercy C, Gao H, et al. Pregnancy in renal transplant recipients: a UK national cohort study. Clin J Am Soc Nephrol 2013; 8:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/43\">",
"      Sturgiss SN, Davison JM. Effect of pregnancy on the long-term function of renal allografts: an update. Am J Kidney Dis 1995; 26:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/44\">",
"      Salmela KT, Kyll&ouml;nen LE, Holmberg C, Gr&ouml;nhagen-Riska C. Impaired renal function after pregnancy in renal transplant recipients. Transplantation 1993; 56:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/45\">",
"      Rahamimov R, Ben-Haroush A, Wittenberg C, et al. Pregnancy in renal transplant recipients: long-term effect on patient and graft survival. A single-center experience. Transplantation 2006; 81:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/46\">",
"      Lindheimer MD, Katz AI. Pregnancy in the renal transplant patient. Am J Kidney Dis 1992; 19:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/47\">",
"      Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 2001; 71:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/48\">",
"      Sifontis NM, Coscia LA, Constantinescu S, et al. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 2006; 82:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/49\">",
"      Jaffer S, Shynlova O, Lye S. Mammalian target of rapamycin is activated in association with myometrial proliferation during pregnancy. Endocrinology 2009; 150:4672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/50\">",
"      Thomson TC, Fitzpatrick KE, Johnson J. Intrinsic and extrinsic mechanisms of oocyte loss. Mol Hum Reprod 2010; 16:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/51\">",
"      European Best Practices Guidelines (Part 2). Nephrol Dial Transplant 2002; 17 (Suppl 4):50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/52\">",
"      Kainz A, Harabacz I, Cowlrick IS, et al. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. Transplantation 2000; 70:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/53\">",
"      Xu LG, Wang HW, Peng WL, et al. Marital status and fertility of 185 male renal transplant recipients in China. J Androl 2008; 29:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11241/abstract/54\">",
"      Zuber J, Anglicheau D, Elie C, et al. Sirolimus may reduce fertility in male renal transplant recipients. Am J Transplant 2008; 8:1471.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7205 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-E927C15C8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_62_11241=[""].join("\n");
var outline_f10_62_11241=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H142691\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFECT OF PREGNANCY ON KIDNEY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Effect on renal function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Kidney biopsy during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EFFECT OF KIDNEY DISEASE ON PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pregnancy in mild to moderate CKD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Drug therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pregnancy in the dialysis patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pregnancy in the renal transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Sirolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Male fertility after transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Evaluation of renal dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      OBSTETRICAL MANAGEMENT OF WOMEN WITH UNDERLYING RENAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H142691\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7205\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7205|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/13/25820\" title=\"table 1\">",
"      Rx pregnant dialysis patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/57/31644\" title=\"table 2\">",
"      FDA categories of immunosuppressive drugs in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33479?source=related_link\">",
"      Acute kidney injury (acute renal failure) in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2072?source=related_link\">",
"      Differential diagnosis of renal allograft dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17562?source=related_link\">",
"      Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/56/22406?source=related_link\">",
"      Mycophenolate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/42/36518?source=related_link\">",
"      Patient information: Systemic lupus erythematosus and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/19/21816?source=related_link\">",
"      Pregnancy in women with diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/45/39641?source=related_link\">",
"      Pregnancy in women with systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36281?source=related_link\">",
"      Pregnancy risks in women with type 1 and type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42487?source=related_link\">",
"      Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=related_link\">",
"      Renal and urinary tract physiology in normal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36484?source=related_link\">",
"      Reproductive and sexual dysfunction in uremic women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/35/27190?source=related_link\">",
"      Sirolimus: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=related_link\">",
"      Therapy of diffuse or focal proliferative lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_62_11242="Cancer-related fatigue: Prevalence, screening and clinical assessment";
var content_f10_62_11242=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cancer-related fatigue: Prevalence, screening and clinical assessment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/62/11242/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/62/11242/contributors\">",
"     Carmen P Escalante, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/62/11242/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/62/11242/contributors\">",
"     Paul J Hesketh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/62/11242/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/62/11242/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/62/11242/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatigue is a common problem in cancer patients. The most important factors contributing to cancer-related fatigue are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cancer therapy, including cytotoxic agents, biologic response modifiers, molecularly targeted therapies, hormonal therapies (eg, androgen deprivation therapy) and radiation therapy (RT)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Metabolic/nutritional/hormonal",
"      </span>",
"      issues, such as anemia, poor nutrition, hypothyroidism, menopause, and dehydration",
"     </li>",
"     <li>",
"      Organ effects, such as heart failure, pulmonary fibrosis, myopathy",
"     </li>",
"     <li>",
"      Other causes, such as pain and its treatment (particularly with opioid analgesics), emotional distress, and sleep disturbance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fatigue is particularly prevalent with multimodality or dose-intense treatment protocols and in patients with metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cancer-related fatigue profoundly affects quality of life (QOL) of both patients and their families, including physical, psychosocial, and",
"    <span class=\"nowrap\">",
"     economic/occupational",
"    </span>",
"    aspects [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Fatigue is routinely identified by patients as one of the most distressing symptoms associated with cancer and its treatment, yet it has been consistently underreported and overlooked as a potentially remediable cause of treatment-related morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/4\">",
"     4",
"    </a>",
"    ]. More recently, screening for and treatment of cancer-related fatigue has become a major focus of supportive care in oncology. Guidelines from expert groups recommend screening for fatigue at the initial visit, at the time that advanced disease is diagnosed, and at all chemotherapy visits [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Here we will review the clinical evaluation of patients with cancer-related fatigue. Treatment of cancer-related fatigue and other functional problems in patients with cancer, including specific rehabilitation issues, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27098?source=see_link\">",
"     \"Cancer-related fatigue: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3690?source=see_link\">",
"     \"Various rehabilitation issues in patients treated for cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43719?source=see_link\">",
"     \"Functional problems in the patient with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer-related fatigue is defined as a persistent, subjective sense of physical, emotional",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and that significantly interferes with usual functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/5\">",
"     5",
"    </a>",
"    ]. Cancer-related fatigue differs from the fatigue that accompanies everyday life, which is usually temporary and relieved by rest.",
"   </p>",
"   <p>",
"    The term asthenia has been proposed to describe the condition of chronic pathologic tiredness in patients with cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/7\">",
"     7",
"    </a>",
"    ]. However, the term fatigue has gained widespread acceptance in the medical literature and is preferentially used in the NCI toxicity grading scale that covers fatigue, asthenia, and malaise (",
"    <a class=\"graphic graphic_table graphicRef60072 \" href=\"UTD.htm?10/32/10763\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Specific diagnostic criteria have been proposed for defining cancer-related fatigue as an independent entity in the International Classification of Diseases, 10th revision (ICD-10) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. At least 6 of 11 criteria must be met to make the diagnosis of cancer-related fatigue (",
"    <a class=\"graphic graphic_table graphicRef61574 \" href=\"UTD.htm?19/24/19852\">",
"     table 2",
"    </a>",
"    ). In studies of diverse patient populations, approximately 10 to 26 percent of subjects are diagnosed as having cancer-related fatigue using this definition [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/10-13\">",
"     10-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of diagnostic criteria such as these provides a greater degree of specificity than the simple question \"Do you feel tired?\", as was used in two national cancer-related fatigue prevalence studies and which results in spuriously high prevalence figures (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Prevalence'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. However, the formal diagnostic criteria as outlined in the ICD-10 are not in widespread use (",
"    <a class=\"graphic graphic_table graphicRef61574 \" href=\"UTD.htm?19/24/19852\">",
"     table 2",
"    </a>",
"    ), and patients do not necessarily need to have a minimum number of criteria to receive a clinical diagnosis of cancer-related fatigue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The true incidence of cancer-related fatigue in cancer patients is difficult to ascertain; published studies are restricted to prevalence data. Estimates are that cancer-related fatigue affects between 15 and 90 percent of cancer patients overall [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/10,14-29\">",
"     10,14-29",
"    </a>",
"    ] and more than 75 percent of those with advanced cancer or bone metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/16,30\">",
"     16,30",
"    </a>",
"    ]. The wide range of these estimates likely reflects variable diagnostic criteria used to define cancer-related fatigue.",
"   </p>",
"   <p>",
"    The prevalence and severity of cancer-related fatigue were studied in two United States national surveys commissioned by the Fatigue Coalition, a multidisciplinary group of practitioners, researchers, and patient advocates [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first survey, 419 cancer patients who were members of 1700 randomly selected American families were interviewed by telephone [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/14\">",
"       14",
"      </a>",
"      ]. Fatigue was defined as a positive response to the single question \"Do you feel tired?\". The majority had solid tumors, and treatment consisted of chemotherapy (59 percent), RT (63 percent), or both (24 percent). More than one-half had received therapy within the last year. In a separate mail survey, 197 of 600 randomly sampled oncologists responded to a questionnaire assessing perceptions and attitudes concerning cancer-related fatigue.",
"      <br/>",
"      <br/>",
"      Overall, 74 percent of patients reported fatigue at some point during the course of their illness, with 32 percent reporting daily fatigue. However, only 50 percent of patients had discussed fatigue with their clinician, and in only one-fourth of cases was any intervention proposed. Patients and oncologists disagreed on the importance of cancer-related fatigue. Although doctors believed that pain affected patients to a greater degree than fatigue, patients thought that cancer-related fatigue adversely affected their daily lives to a greater degree than pain.",
"     </li>",
"     <li>",
"      Similar results were noted in a second telephone survey of 379 patients who had received chemotherapy with or without RT for some form of malignancy, identified from a representative sample of 6125 families obtained from the US Bureau of Census [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/15\">",
"       15",
"      </a>",
"      ]. Fatigue, defined the same way as in the first study, was present on at least some days of the month during chemotherapy in 76 percent of patients, with 30 percent suffering from fatigue on a daily basis. Patients reported fatigue as the symptom that most affected QOL, followed by nausea, depression, and pain. The economic impact of cancer-related fatigue was considerable. Of the 177 employed patients, 75 percent changed their employment status as a result of fatigue, and 65 percent reported that their caregivers had to take at least one day (mean 4.5 days) off from work in a typical month.",
"     </li>",
"     <li>",
"      Comparable findings also were noted in a survey of patients and health care practitioners conducted by the All-Ireland Fatigue Coalition [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/31\">",
"       31",
"      </a>",
"      ]. However, all of these surveys consist of retrospective cross-sectional data and are biased by recall and the use of nonvalidated diagnostic criteria.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As expected, a lower prevalence of cancer-related fatigue has been found in studies applying stricter diagnostic criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/10,11,32\">",
"     10,11,32",
"    </a>",
"    ]. This was illustrated in a validation study of the cancer-related fatigue diagnostic criteria being proposed for use in the ICD-10 (",
"    <a class=\"graphic graphic_table graphicRef61574 \" href=\"UTD.htm?19/24/19852\">",
"     table 2",
"    </a>",
"    ) that was carried out in 379 individuals receiving chemotherapy with or without RT [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/10\">",
"     10",
"    </a>",
"    ]. Overall, 141 patients (37 percent) had fatigue for at least two weeks in the prior month (ie, one of the proposed criteria), although only 66 (17 percent) met the proposed definition of cancer-related fatigue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Time course",
"    </span>",
"    &nbsp;&mdash;&nbsp;An additional problem with prevalence data is that cancer-related fatigue tends to fluctuate over the course of cancer treatment. For patients receiving chemotherapy, cancer-related fatigue is commonly cyclic and worst when blood counts are at their nadir (usually 10 to 14 days following treatment initiation). In contrast, the intensity of cancer-related fatigue in patients undergoing RT typically peaks toward the end of therapy, gradually decreasing thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/26,33-39\">",
"     26,33-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although cancer-related fatigue is most prevalent during active cancer therapy, a sense of fatigue may persist in survivors for months or even years after cessation of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/28,37,40-50\">",
"     28,37,40-50",
"    </a>",
"    ]. A minority of patients who are presumably cured of their cancer are so debilitated by fatigue that they are still unable to work or regain their premorbid lifestyles years after completing treatment. Because of the lack of objective findings, many have problems maintaining disability status, causing additional stress and anxiety for themselves and their families.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms that are responsible for cancer-related fatigue are poorly understood. Major obstacles to defining the relevant pathophysiology include the inherent subjectivity of fatigue, the difficulty in establishing objective behavioral correlates, and the wide variety of phenomena (including conditions that are unrelated to cancer or its treatment) that contribute to fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of pathophysiologic hypotheses have been proposed for cancer-related fatigue, although none have been proven:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Direct central nervous system toxicity of cancer treatment (ie, drugs that cross the blood-brain barrier, cranial irradiation)",
"     </li>",
"     <li>",
"      Anemia",
"     </li>",
"     <li>",
"      Loss of muscle mass, defective muscle energy metabolism,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      abnormalities in the generation or use of ATP [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Neurophysiologic skeletal muscle changes (the so-called vagal afferent hypothesis) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Chronic stress response, possibly mediated through the hypothalamic pituitary axis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/19,52\">",
"       19,52",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Systemic inflammatory response [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/53-56\">",
"       53-56",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Immune activation associated with production of proinflammatory cytokines [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/57\">",
"       57",
"      </a>",
"      ]",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      circulating T cells [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/58\">",
"       58",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Disrupted sleep or circadian rhythms [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/59-63\">",
"       59-63",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hormonal changes (eg, premature menopause in women)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A detailed description of these hypotheses and the data upon which they are based is beyond the scope of this review and provided elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/51,64,65\">",
"     51,64,65",
"    </a>",
"    ]. What follows is a brief overview of the mechanisms underlying cancer-related fatigue that are directly related to cancer therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Chemotherapy and molecularly targeted therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy and molecularly targeted therapy with small molecule tyrosine kinase inhibitors or therapeutic MoAbs may contribute directly to the development of cancer-related fatigue. Among the agents that are most commonly associated with fatigue are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    (80 to 90 percent),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    (30 to 50 percent),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    (15 to 30 percent). Other conventional cytotoxic agents that cross the blood brain barrier (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    ) may also induce fatigue via a direct neurotoxic effect [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These agents can also indirectly contribute to cancer-related fatigue by causing or interacting with other mechanisms that induce or exacerbate fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/16\">",
"     16",
"    </a>",
"    ]. Examples include chemotherapy-induced premature menopause [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/67,68\">",
"     67,68",
"    </a>",
"    ] and the higher rates of posttreatment fatigue that have been seen in patients receiving chemotherapy who have preexisting poor mental health [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1447?source=see_link\">",
"     \"Ovarian failure due to anticancer drugs and radiation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41496?source=see_link\">",
"     \"Acute side effects of adjuvant chemotherapy for early stage breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long-term effects of chemotherapy on organ function may also be responsible for cancer-related fatigue. Some examples are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    -induced hypothyroidism, chronic heart failure from anthracycline-induced cardiomyopathy and bleomycin-related pulmonary dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=see_link\">",
"     \"Bleomycin-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Biologic response modifiers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatigue is nearly universal in patients receiving interferon (IFN) or interleukin-2 (IL-2) for melanoma or renal cell cancer.",
"   </p>",
"   <p>",
"    Mechanisms that may contribute to this effect include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disturbances of the hypothalamic-pituitary-adrenal axis, affecting levels of ACTH and corticotrophin-releasing hormone, and ultimately the secretion of cortisol by the adrenal cortex [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/71-73\">",
"       71-73",
"      </a>",
"      ]. This may be mediated through the production of proinflammatory cytokines or by a direct inhibition.",
"     </li>",
"     <li>",
"      Effects on neurotransmitter levels (eg, dopamine, serotonin).",
"     </li>",
"     <li>",
"      Drug-induced hypothyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/74-77\">",
"       74-77",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Androgen deprivation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatigue is a common problem in men undergoing androgen deprivation therapy for prostate cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=see_link&amp;anchor=H25#H25\">",
"     \"Side effects of androgen deprivation therapy\", section on 'Fatigue'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatigue is a common early and chronic side effect of RT. It is reported in up to 80 and 30 percent of patients during RT and at follow-up visits, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/2,78-80\">",
"     2,78-80",
"    </a>",
"    ]. In general, fatigue tends to worsen during treatment.",
"   </p>",
"   <p>",
"    Fatigue is most common in patients receiving cranial irradiation and presumably related to direct effects on normal brain parenchyma or radiation-induced edema. This is often enhanced by the concomitant use of high-dose glucocorticoids. Although most patients have mild to moderate fatigue, a rare somnolence syndrome has been described. The etiology of this rare complication of cranial irradiation is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H13#H13\">",
"     \"Complications of cranial irradiation\", section on 'Somnolence and the somnolence syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathophysiology underlying fatigue in patients undergoing RT to extracranial sites is unclear. Sometimes anemia is contributory, but other mechanisms are probably operative [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/81\">",
"     81",
"    </a>",
"    ]. As examples, in patients treated for pelvic malignancies, severe diarrhea during treatment may exacerbate fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/82\">",
"     82",
"    </a>",
"    ], hypothyroidism may be a consequence of neck irradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/83\">",
"     83",
"    </a>",
"    ], and fatigue may accompany the concurrent use of androgen deprivation therapy in men receiving RT for prostate cancer. Psychological mechanisms have been proposed to explain fatigue in women receiving RT for early breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/2\">",
"     2",
"    </a>",
"    ], whereas a decline in neuromuscular efficiency has been proposed among men undergoing RT for prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the potential contributory factors to postoperative fatigue are operative blood loss, medication effects, decreased ventilatory capacity, immobilization, infection, perioperative nutritional depletion, altered sleep patterns, and anxiety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Contribution of anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia is common in cancer patients, both as a consequence of the cancer itself (anemia of chronic disease, iron deficiency anemia due to gastrointestinal blood loss) or its treatment (surgery, systemic therapy, and RT). The full spectrum of other causes of anemia also needs to be considered in these patients (ie, hemolysis, nutritional deficiency). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link\">",
"     \"Approach to the adult patient with anemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23914?source=see_link\">",
"     \"Hematologic consequences of malignancy: Anemia and bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although early studies were unable to demonstrate a clear correlation between hemoglobin levels and the severity of cancer-related fatigue, a direct relationship between anemia, fatigue, and QOL has been seen in later studies that used more refined evaluation instruments, such as the Functional Assessment of Cancer Therapy-Anemia (FACT-An) subscale (",
"    <a class=\"graphic graphic_table graphicRef76886 \" href=\"UTD.htm?7/4/7244\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/7,85-89\">",
"     7,85-89",
"    </a>",
"    ]. Correction of anemia has been associated with an improvement in health-related QOL [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10233723\">",
"    <span class=\"h2\">",
"     Male hypogonadism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypogonadism affects two-thirds of men with advanced cancer. Previous studies have shown that low testosterone levels in men with cancer are associated with fatigue, anorexia, depression, and insomnia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/91\">",
"     91",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=see_link\">",
"     \"Clinical features and diagnosis of male hypogonadism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=see_link\">",
"     \"Causes of secondary hypogonadism in males\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLINICAL ASSESSMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;National Comprehensive Cancer Network (NCCN) guidelines suggest that all patients with malignant disease be screened for cancer-related fatigue at the initial visit, when the diagnosis of advanced disease is made and at each chemotherapy visit [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/5\">",
"     5",
"    </a>",
"    ]. They suggest the use of a single screening question using a visual analog scale (VAS, \"How would you rate your fatigue on a scale of 0 to 10\"), with 0 representing no fatigue and 10 the worst imaginable fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/5,92\">",
"     5,92",
"    </a>",
"    ]. Mild, moderate, and severe fatigue are represented by scores of 1 to 3, 4 to 6, and 7 to 10, respectively.",
"   </p>",
"   <p>",
"    Other instruments have been developed and validated to quantify cancer-related fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/93\">",
"     93",
"    </a>",
"    ]. Some of the more commonly used and best validated are the fatigue and anemia subscales of the Functional Assessment of Cancer Therapy instrument (FACT-F discussed above), the Brief Fatigue Inventory [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/92\">",
"     92",
"    </a>",
"    ], the bidimensional fatigue scale [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/94,95\">",
"     94,95",
"    </a>",
"    ], the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/96\">",
"     96",
"    </a>",
"    ], and the EORTC QOL questionnaire (EORTC QLQ C30), fatigue subscale [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because fatigue is subjective, the clinician must rely upon patient self-reports to assess its presence and severity, which can then be supported by additional sources of information, such as physical examination, laboratory data, or the descriptions of family members.",
"   </p>",
"   <p>",
"    Even when asked, patients may be hesitant to report fatigue to their healthcare provider [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/4,98\">",
"     4,98",
"    </a>",
"    ]. Patients may believe that fatigue is an expected and inevitable side effect of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/14,99\">",
"     14,99",
"    </a>",
"    ], fear that they will be labeled a \"complainer\", or be afraid that they will receive suboptimal cancer treatment if they admit to being fatigued. Patients also may be anxious because they believe that fatigue is a sign of recurrent or progressing disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Need for further evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for further evaluation is based on level of cancer-related fatigue. If the reported intensity level is mild (VAS or BFI score 1 to 3) and does not interfere with the activities of daily living (ADLs), the patient can be reassured and educated as to some common strategies to minimize energy expenditure (",
"    <a class=\"graphic graphic_table graphicRef73183 \" href=\"UTD.htm?16/47/17149\">",
"     table 4",
"    </a>",
"    ). ADLs includes basic activities such as bathing, dressing, grooming, toileting, continence, eating, transferring and walking, as well as \"instrumental\" ADLs (IADLs) such as traveling, shopping, preparing meals, doing housework, taking medications, managing money, and using the telephone. Periodic reassessment should be undertaken during therapy. Patients who are no longer receiving active therapy as well as long-term cancer survivors must still be monitored for cancer-related fatigue, which may persist beyond the period of active treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Moderate to severe fatigue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moderate to severe cancer-related fatigue requires a more focused history and physical examination to search for potentially reversible or treatable contributory factors.",
"   </p>",
"   <p>",
"    The components of an in-depth fatigue assessment include the onset, duration and pattern of fatigue, and associated or alleviating factors. The effect of cancer-related fatigue on physical and cognitive functioning and on the patient's ADLs or enjoyment of life should be noted. A comprehensive review of systems is warranted to ascertain the various organ systems affected, and to direct the physical examination and diagnostic work-up. Additional relevant information includes a history of smoking, alcohol and any illicit drug use, work history, and review of activity level and exercise tolerance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Assessment of disease status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accurate assessment of the patient's current disease status, type of treatment, and response to treatment is an important component of the initial evaluation. If it is determined that fatigue is unrelated to disease progression or recurrence, informing patients and their family members of this fact may substantially reduce anxiety levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications are an often overlooked major contributor to fatigue. Review of all medications (both prescribed and over the counter) may reveal potential side effects or drug-drug interactions. As examples, beta-blockers can cause bradycardia and exertional fatigue, while excessive drowsiness may result from combinations of opioids with antidepressants or antihistamines, or incorrectly dosed pain medications. In some cases, altering the dose or dosing interval of a medication may substantially improve fatigue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9290?source=see_link&amp;anchor=H6#H6\">",
"     \"Cancer pain management with opioids: Prevention and management of side effects\", section on 'Somnolence and mental clouding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Treatable contributing factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors that are often causally related to cancer-related fatigue should be specifically assessed, including anemia, pain, emotional distress, sleep disturbance, nutrition and electrolyte disturbances (",
"    <a class=\"graphic graphic_table graphicRef64018 \" href=\"UTD.htm?4/38/4715\">",
"     table 5",
"    </a>",
"    ), activity level, and the presence of other comorbidities.",
"   </p>",
"   <p>",
"    Comorbidities that may be unrelated to the cancer or its treatment (eg, infection, cardiopulmonary, renal, hepatic, neurologic, or endocrine dysfunction) may contribute significantly to symptoms of fatigue. Cancer-related fatigue may be improved by optimizing treatment for conditions that have been previously unrecognized (eg, hypothyroidism) or suboptimally treated (eg, recurrent heart failure because of doxorubicin-induced cardiomyopathy).",
"   </p>",
"   <p>",
"    As noted above, hypothyroidism may be related to irradiation for lymphoma, head and neck cancer, or breast cancer, or total body irradiation prior to hematopoietic stem cell transplantation. In addition, several anticancer drugs (most notably",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    ) can cause hypothyroidism.",
"   </p>",
"   <p>",
"    If any of these factors known to be associated with cancer-related fatigue are identified, they should be treated as the initial approach to fatigue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uncontrolled cancer pain may contribute to cancer-related fatigue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Emotional disturbance/mood disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatigue seldom occurs by itself, and it commonly clusters with emotional distress, mood disorders, sleep disturbance,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pain [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/100-104\">",
"     100-104",
"    </a>",
"    ]. In particular, there is a strong correlation between fatigue and depression [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/62,105-110\">",
"     62,105-110",
"    </a>",
"    ], and in some cases, it may be difficult to distinguish between the two as the source of distress [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/110,111\">",
"     110,111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The precise relationship between cancer-related fatigue and emotional distress is not clear. Fatigue can be a symptom of depression",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anxiety, but high levels of fatigue also can result in emotional distress when valued roles and activities are affected. Some data support the view that depression and fatigue, although linked, follow a different time course in patients with cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/112\">",
"     112",
"    </a>",
"    ] and that they respond differentially to therapeutic intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/113\">",
"     113",
"    </a>",
"    ]. As an example, placebo-controlled, randomized trials in patients undergoing cancer treatment have failed to demonstrate any improvement in cancer-related fatigue in patients randomly assigned to receive an antidepressant despite its benefit in reducing symptoms of depression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27098?source=see_link&amp;anchor=H14#H14\">",
"     \"Cancer-related fatigue: Treatment\", section on 'Antidepressants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Sleep disturbance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep disturbances in patients with cancer range from hypersomnia to insomnia. Although patients undergoing active cancer treatment tend to spend greater amounts of time resting and sleeping than individuals without cancer, sleep patterns often are disrupted, resulting in poor quality of sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/59,114,115\">",
"     59,114,115",
"    </a>",
"    ]. Insomnia symptoms affect between 30 and 50 percent of cancer patients, and 20 to 40 percent meet the diagnostic criteria for insomnia syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/116-120\">",
"     116-120",
"    </a>",
"    ]. Sleep-wake disturbances may persist in long-term survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Poor sleep hygiene (eg, frequent daytime naps late in the day) may contribute to inadequate nighttime rest. Medications may also contribute to insomnia. Patients with a history suggestive of sleep apnea should be referred for formal sleep evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4758?source=see_link\">",
"     \"Overview of insomnia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link\">",
"     \"Sleep related breathing disorders in adults: Definitions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritional assessment should include an evaluation for weight gain or loss, changes in and impediments to adequate caloric intake, and fluid and electrolyte imbalances. Oral intake can be adversely affected by anorexia, nausea, vomiting, mucositis, odynophagia, bowel obstruction, or constipation. Imbalances in sodium, potassium, calcium, and magnesium may be associated with fatigue, which is potentially reversible with adequate supplementation (",
"    <a class=\"graphic graphic_table graphicRef64018 \" href=\"UTD.htm?4/38/4715\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Efforts directed at improving or maintaining nutritional status can decrease or prevent cancer-related fatigue. Patients with poor dietary intake or decreased absorption may need further assessment by a nutritionist. Treatment-related side effects such as nausea, vomiting, or diarrhea should be minimized. A detailed discussion of cancer-associated anorexia and cachexia is provided elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=see_link\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42362?source=see_link\">",
"     \"Enterotoxicity of chemotherapeutic agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17960?source=see_link\">",
"     \"Clinical features and pathogenesis of cancer cachexia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5113?source=see_link\">",
"     \"Pharmacologic management of cancer anorexia/cachexia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Activity level",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with moderate to severe cancer-related fatigue should be asked about their overall activity level, including the influence of deconditioning. Patients should be asked whether they are able to maintain their basic and instrumental ADLs (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Need for further evaluation'",
"    </a>",
"    above) and whether they participate in either formal or informal exercise programs. Although exercise may be beneficial in improving cancer-related fatigue in certain patients, the level of deconditioning must be assessed before recommending an exercise program. If a severely deconditioned patient begins an exercise program too rapidly, complications may develop (eg, muscle strain) that may leave them discouraged and increasingly fatigued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27098?source=see_link&amp;anchor=H7#H7\">",
"     \"Cancer-related fatigue: Treatment\", section on 'Exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/4/29762?source=see_link\">",
"       \"Patient information: When your cancer treatment makes you tired (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer-related fatigue is a common, distressing, and potentially treatable condition. The most important factors contributing to cancer-related fatigue are treatment with cytotoxic chemotherapy, biologic response modifiers, molecularly targeted therapy (particularly the small molecular tyrosine kinase inhibitors and the therapeutic monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    ) or radiation therapy, anemia, pain (and its treatment), emotional distress, sleep disturbance, poor nutrition, and other comorbidities. Although most common during active cancer therapy, cancer-related fatigue may affect patients long after cancer treatment has been completed. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be screened for fatigue at the initial visit, at the time that advanced disease is diagnosed, and at all chemotherapy visits [",
"    <a class=\"abstract\" href=\"UTD.htm?10/62/11242/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. A simple visual analog score (VAS) using a rating scale (\"How would you rate your fatigue on a scale of 0 to 10\", with 0 representing no fatigue and 10 the worst imaginable fatigue) is a reasonable approach to screening. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Screening'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Diagnostic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mild fatigue (VAS score 1 to 3) that does not interfere with activities of daily living (ADLs) can be reassured and counseled as to coping strategies that conserve energy (",
"    <a class=\"graphic graphic_table graphicRef73183 \" href=\"UTD.htm?16/47/17149\">",
"     table 4",
"    </a>",
"    ). Fatigue that is moderate to severe (4 or higher on the VAS scale) or interferes with basic or instrumental ADLs requires a comprehensive fatigue evaluation with a complete history, review of systems, physical examination, diagnostic studies as indicated (",
"    <a class=\"graphic graphic_table graphicRef64018 \" href=\"UTD.htm?4/38/4715\">",
"     table 5",
"    </a>",
"    ), and objective assessment of associated symptoms. Factors that are often causally related to cancer-related fatigue that should be specifically assessed include anemia, pain (and its treatment), emotional",
"    <span class=\"nowrap\">",
"     distress/mood",
"    </span>",
"    disturbance, difficulties with sleep, poor nutrition and electrolyte disturbances, activity level, the presence of comorbidities such as cardiac or pulmonary disease, and low testosterone in men with symptoms suggestive of hypogonadism. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Moderate to severe fatigue'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/1\">",
"      Hauser K, Walsh D, Rybicki LA, et al. Fatigue in advanced cancer: a prospective study. Am J Hosp Palliat Care 2008; 25:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/2\">",
"      Dagnelie PC, Pijls-Johannesma MC, Lambin P, et al. Impact of fatigue on overall quality of life in lung and breast cancer patients selected for high-dose radiotherapy. Ann Oncol 2007; 18:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/3\">",
"      Gupta D, Lis CG, Grutsch JF. The relationship between cancer-related fatigue and patient satisfaction with quality of life in cancer. J Pain Symptom Manage 2007; 34:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/4\">",
"      Stone P, Richardson A, Ream E, et al. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol 2000; 11:971.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/6\">",
"      Dy SM, Lorenz KA, Naeim A, et al. Evidence-based recommendations for cancer fatigue, anorexia, depression, and dyspnea. J Clin Oncol 2008; 26:3886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/7\">",
"      Sobrero A, Puglisi F, Guglielmi A, et al. Fatigue: a main component of anemia symptomatology. Semin Oncol 2001; 28:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/8\">",
"      Cella D, Peterman A, Passik S, et al. Progress toward guidelines for the management of fatigue. Oncology (Williston Park) 1998; 12:369.",
"     </a>",
"    </li>",
"    <li>",
"     International Classification of Diseases, Tenth Revision (ICD-10). www.cdc.gov/nchs/about/major/dvs/icd10des.htm (Accessed on February 28, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/10\">",
"      Cella D, Davis K, Breitbart W, et al. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 2001; 19:3385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/11\">",
"      Andrykowski MA, Schmidt JE, Salsman JM, et al. Use of a case definition approach to identify cancer-related fatigue in women undergoing adjuvant therapy for breast cancer. J Clin Oncol 2005; 23:6613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/12\">",
"      Sadler IJ, Jacobsen PB, Booth-Jones M, et al. Preliminary evaluation of a clinical syndrome approach to assessing cancer-related fatigue. J Pain Symptom Manage 2002; 23:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/13\">",
"      Murphy H, Alexander S, Stone P. Investigation of diagnostic criteria for cancer-related fatigue syndrome in patients with advanced cancer: a feasibility study. Palliat Med 2006; 20:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/14\">",
"      Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997; 34:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/15\">",
"      Curt GA, Breitbart W, Cella D, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 2000; 5:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/16\">",
"      Stasi R, Abriani L, Beccaglia P, et al. Cancer-related fatigue: evolving concepts in evaluation and treatment. Cancer 2003; 98:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/17\">",
"      Flechtner H, Bottomley A. Fatigue and quality of life: lessons from the real world. Oncologist 2003; 8 Suppl 1:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/18\">",
"      de Jong N, Courtens AM, Abu-Saad HH, Schouten HC. Fatigue in patients with breast cancer receiving adjuvant chemotherapy: a review of the literature. Cancer Nurs 2002; 25:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/19\">",
"      Morrow GR, Andrews PL, Hickok JT, et al. Fatigue associated with cancer and its treatment. Support Care Cancer 2002; 10:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/20\">",
"      Holzner B, Kemmler G, Meraner V, et al. Fatigue in ovarian carcinoma patients: a neglected issue? Cancer 2003; 97:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/21\">",
"      Respini D, Jacobsen PB, Thors C, et al. The prevalence and correlates of fatigue in older cancer patients. Crit Rev Oncol Hematol 2003; 47:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/22\">",
"      Wang XS, Giralt SA, Mendoza TR, et al. Clinical factors associated with cancer-related fatigue in patients being treated for leukemia and non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/23\">",
"      Edwards JL, Gibson F, Richardson A, et al. Fatigue in adolescents with and following a cancer diagnosis: developing an evidence base for practice. Eur J Cancer 2003; 39:2671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/24\">",
"      Fernandes R, Stone P, Andrews P, et al. Comparison between fatigue, sleep disturbance, and circadian rhythm in cancer inpatients and healthy volunteers: evaluation of diagnostic criteria for cancer-related fatigue. J Pain Symptom Manage 2006; 32:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/25\">",
"      Chang VT, Hwang SS, Feuerman M, Kasimis BS. Symptom and quality of life survey of medical oncology patients at a veterans affairs medical center: a role for symptom assessment. Cancer 2000; 88:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/26\">",
"      Smets EM, Visser MR, Willems-Groot AF, et al. Fatigue and radiotherapy: (A) experience in patients undergoing treatment. Br J Cancer 1998; 78:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/27\">",
"      Hickok JT, Morrow GR, McDonald S, Bellg AJ. Frequency and correlates of fatigue in lung cancer patients receiving radiation therapy: implications for management. J Pain Symptom Manage 1996; 11:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/28\">",
"      Liavaag AH, D&oslash;rum A, Foss&aring; SD, et al. Controlled study of fatigue, quality of life, and somatic and mental morbidity in epithelial ovarian cancer survivors: how lucky are the lucky ones? J Clin Oncol 2007; 25:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/29\">",
"      Teunissen SC, Wesker W, Kruitwagen C, et al. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage 2007; 34:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/30\">",
"      Stone P, Hardy J, Broadley K, et al. Fatigue in advanced cancer: a prospective controlled cross-sectional study. Br J Cancer 1999; 79:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/31\">",
"      Eatock MM, Dillon E, Corcoran B, et al. Cancer fatigue in Ireland: All Ireland Fatigue Coalition professional and interim patient survey (abstract). Proc Am Soc Clin Oncol 2003; 22:764a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/32\">",
"      Forlenza MJ, Hall P, Lichtenstein P, et al. Epidemiology of cancer-related fatigue in the Swedish twin registry. Cancer 2005; 104:2022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/33\">",
"      Janda M, Gerstner N, Obermair A, et al. Quality of life changes during conformal radiation therapy for prostate carcinoma. Cancer 2000; 89:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/34\">",
"      Greenberg DB, Sawicka J, Eisenthal S, Ross D. Fatigue syndrome due to localized radiation. J Pain Symptom Manage 1992; 7:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/35\">",
"      Geinitz H, Zimmermann FB, Stoll P, et al. Fatigue, serum cytokine levels, and blood cell counts during radiotherapy of patients with breast cancer. Int J Radiat Oncol Biol Phys 2001; 51:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/36\">",
"      Irvine DM, Vincent L, Graydon JE, Bubela N. Fatigue in women with breast cancer receiving radiation therapy. Cancer Nurs 1998; 21:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/37\">",
"      Smets EM, Visser MR, Willems-Groot AF, et al. Fatigue and radiotherapy: (B) experience in patients 9 months following treatment. Br J Cancer 1998; 78:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/38\">",
"      Monga U, Kerrigan AJ, Thornby J, Monga TN. Prospective study of fatigue in localized prostate cancer patients undergoing radiotherapy. Radiat Oncol Investig 1999; 7:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/39\">",
"      Magnan MA, Mood DW. The effects of health state, hemoglobin, global symptom distress, mood disturbance, and treatment site on fatigue onset, duration, and distress in patients receiving radiation therapy. Oncol Nurs Forum 2003; 30:E33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/40\">",
"      Servaes P, Verhagen S, Schreuder HW, et al. Fatigue after treatment for malignant and benign bone and soft tissue tumors. J Pain Symptom Manage 2003; 26:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/41\">",
"      R&uuml;ffer JU, Flechtner H, Tralls P, et al. Fatigue in long-term survivors of Hodgkin's lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG). Eur J Cancer 2003; 39:2179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/42\">",
"      Foss&aring; SD, Dahl AA, Loge JH. Fatigue, anxiety, and depression in long-term survivors of testicular cancer. J Clin Oncol 2003; 21:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/43\">",
"      Arndt V, Merx H, Stegmaier C, et al. Persistence of restrictions in quality of life from the first to the third year after diagnosis in women with breast cancer. J Clin Oncol 2005; 23:4945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/44\">",
"      Meeske K, Smith AW, Alfano CM, et al. Fatigue in breast cancer survivors two to five years post diagnosis: a HEAL Study report. Qual Life Res 2007; 16:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/45\">",
"      Loge JH, Abrahamsen AF, Ekeberg O, Kaasa S. Hodgkin's disease survivors more fatigued than the general population. J Clin Oncol 1999; 17:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/46\">",
"      Bower JE, Ganz PA, Desmond KA, et al. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol 2000; 18:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/47\">",
"      Andrykowski MA, Curran SL, Lightner R. Off-treatment fatigue in breast cancer survivors: a controlled comparison. J Behav Med 1998; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/48\">",
"      Hjermstad MJ, Foss&aring; SD, Oldervoll L, et al. Fatigue in long-term Hodgkin's Disease survivors: a follow-up study. J Clin Oncol 2005; 23:6587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/49\">",
"      Jacobsen PB, Donovan KA, Small BJ, et al. Fatigue after treatment for early stage breast cancer: a controlled comparison. Cancer 2007; 110:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/50\">",
"      Braun IM, Greenberg DB, Pirl WF. Evidenced-based report on the occurrence of fatigue in long-term cancer survivors. J Natl Compr Canc Netw 2008; 6:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/51\">",
"      Gutstein HB. The biologic basis of fatigue. Cancer 2001; 92:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/52\">",
"      Lundstr&ouml;m S, F&uuml;rst CJ. Symptoms in advanced cancer: relationship to endogenous cortisol levels. Palliat Med 2003; 17:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/53\">",
"      Scott HR, McMillan DC, Brown DJ, et al. A prospective study of the impact of weight loss and the systemic inflammatory response on quality of life in patients with inoperable non-small cell lung cancer. Lung Cancer 2003; 40:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/54\">",
"      Cleeland CS, Bennett GJ, Dantzer R, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 2003; 97:2919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/55\">",
"      Scott HR, McMillan DC, Forrest LM, et al. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 2002; 87:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/56\">",
"      Collado-Hidalgo A, Bower JE, Ganz PA, et al. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res 2006; 12:2759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/57\">",
"      Bower JE, Ganz PA, Aziz N, Fahey JL. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 2002; 64:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/58\">",
"      Bower JE, Ganz PA, Aziz N, et al. T-cell homeostasis in breast cancer survivors with persistent fatigue. J Natl Cancer Inst 2003; 95:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/59\">",
"      Parker KP, Bliwise DL, Ribeiro M, et al. Sleep/Wake patterns of individuals with advanced cancer measured by ambulatory polysomnography. J Clin Oncol 2008; 26:2464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/60\">",
"      Ancoli-Israel S, Moore PJ, Jones V. The relationship between fatigue and sleep in cancer patients: a review. Eur J Cancer Care (Engl) 2001; 10:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/61\">",
"      Miaskowski C, Lee KA. Pain, fatigue, and sleep disturbances in oncology outpatients receiving radiation therapy for bone metastasis: a pilot study. J Pain Symptom Manage 1999; 17:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/62\">",
"      Roscoe JA, Morrow GR, Hickok JT, et al. Temporal interrelationships among fatigue, circadian rhythm and depression in breast cancer patients undergoing chemotherapy treatment. Support Care Cancer 2002; 10:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/63\">",
"      Savard J, Davidson JR, Ivers H, et al. The association between nocturnal hot flashes and sleep in breast cancer survivors. J Pain Symptom Manage 2004; 27:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/64\">",
"      Levy MR. Cancer fatigue: a neurobiological review for psychiatrists. Psychosomatics 2008; 49:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/65\">",
"      Ryan JL, Carroll JK, Ryan EP, et al. Mechanisms of cancer-related fatigue. Oncologist 2007; 12 Suppl 1:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/66\">",
"      Stone P, Richards M, Hardy J. Fatigue in patients with cancer. Eur J Cancer 1998; 34:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/67\">",
"      Tchen N, Juffs HG, Downie FP, et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 2003; 21:4175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/68\">",
"      Fan HG, Hou&eacute;d&eacute;-Tchen N, Yi QL, et al. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol 2005; 23:8025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/69\">",
"      Nieboer P, Buijs C, Rodenhuis S, et al. Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study. J Clin Oncol 2005; 23:8296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/70\">",
"      Knobel H, H&aring;vard Loge J, Lund MB, et al. Late medical complications and fatigue in Hodgkin's disease survivors. J Clin Oncol 2001; 19:3226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/71\">",
"      Kirkwood JM, Bender C, Agarwala S, et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 2002; 20:3703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/72\">",
"      Sundin DJ, Wolin MJ. Toxicity management in patients receiving low-dose aldesleukin therapy. Ann Pharmacother 1998; 32:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/73\">",
"      Malik UR, Makower DF, Wadler S. Interferon-mediated fatigue. Cancer 2001; 92:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/74\">",
"      Englebienne P, Verhas M, Herst CV, De Meirleir K. Type I interferons induce proteins susceptible to act as thyroid receptor (TR) corepressors and to signal the TR for destruction by the proteasome: possible etiology for unexplained chronic fatigue. Med Hypotheses 2003; 60:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/75\">",
"      Jones TH, Wadler S, Hupart KH. Endocrine-mediated mechanisms of fatigue during treatment with interferon-alpha. Semin Oncol 1998; 25:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/76\">",
"      Atkins MB, Mier JW, Parkinson DR, et al. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 1988; 318:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/77\">",
"      Weijl NI, Van der Harst D, Brand A, et al. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol 1993; 11:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/78\">",
"      Jereczek-Fossa BA, Marsiglia HR, Orecchia R. Radiotherapy-related fatigue. Crit Rev Oncol Hematol 2002; 41:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/79\">",
"      Brown P, Clark MM, Atherton P, et al. Will improvement in quality of life (QOL) impact fatigue in patients receiving radiation therapy for advanced cancer? Am J Clin Oncol 2006; 29:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/80\">",
"      Hickok JT, Morrow GR, Roscoe JA, et al. Occurrence, severity, and longitudinal course of twelve common symptoms in 1129 consecutive patients during radiotherapy for cancer. J Pain Symptom Manage 2005; 30:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/81\">",
"      Ahlberg K, Ekman T, Gaston-Johansson F. Levels of fatigue compared to levels of cytokines and hemoglobin during pelvic radiotherapy: a pilot study. Biol Res Nurs 2004; 5:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/82\">",
"      Wang XS, Janjan NA, Guo H, et al. Fatigue during preoperative chemoradiation for resectable rectal cancer. Cancer 2001; 92:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/83\">",
"      Jereczek-Fossa BA, Santoro L, Alterio D, et al. Fatigue during head-and-neck radiotherapy: prospective study on 117 consecutive patients. Int J Radiat Oncol Biol Phys 2007; 68:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/84\">",
"      Monga U, Jaweed M, Kerrigan AJ, et al. Neuromuscular fatigue in prostate cancer patients undergoing radiation therapy. Arch Phys Med Rehabil 1997; 78:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/85\">",
"      Yellen SB, Cella DF, Webster K, et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997; 13:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/86\">",
"      Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997; 34:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/87\">",
"      Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19:2875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/88\">",
"      Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002; 94:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/89\">",
"      Cella D, Zagari MJ, Vandoros C, et al. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 2003; 21:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/90\">",
"      Littlewood TJ, Kallich JD, San Miguel J, et al. Efficacy of darbepoetin alfa in alleviating fatigue and the effect of fatigue on quality of life in anemic patients with lymphoproliferative malignancies. J Pain Symptom Manage 2006; 31:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/91\">",
"      Del Fabbro E, Hui D, Nooruddin ZI, et al. Associations among hypogonadism, C-reactive protein, symptom burden, and survival in male cancer patients with cachexia: a preliminary report. J Pain Symptom Manage 2010; 39:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/92\">",
"      Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 1999; 85:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/93\">",
"      Wu HS, McSweeney M. Assessing fatigue in persons with cancer: an instrument development and testing study. Cancer 2004; 101:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/94\">",
"      Alexander S, Minton O, Stone PC. Evaluation of screening instruments for cancer-related fatigue syndrome in breast cancer survivors. J Clin Oncol 2009; 27:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/95\">",
"      Chalder T, Berelowitz G, Pawlikowska T, et al. Development of a fatigue scale. J Psychosom Res 1993; 37:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/96\">",
"      Stein KD, Jacobsen PB, Blanchard CM, Thors C. Further validation of the multidimensional fatigue symptom inventory-short form. J Pain Symptom Manage 2004; 27:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/97\">",
"      Minton O, Stone P. A systematic review of the scales used for the measurement of cancer-related fatigue (CRF). Ann Oncol 2009; 20:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/98\">",
"      Passik SD, Kirsh KL, Donaghy K, et al. Patient-related barriers to fatigue communication: initial validation of the fatigue management barriers questionnaire. J Pain Symptom Manage 2002; 24:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/99\">",
"      Patrick DL, Ferketich SL, Frame PS, et al. National Institutes of Health State-of-the-Science Conference Statement: Symptom Management in Cancer: Pain, Depression, and Fatigue, July 15-17, 2002. J Natl Cancer Inst 2003; 95:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/100\">",
"      Escalante CP, Grover T, Johnson BA, et al. A fatigue clinic in a comprehensive cancer center: design and experiences. Cancer 2001; 92:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/101\">",
"      Jacobsen PB, Hann DM, Azzarello LM, et al. Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J Pain Symptom Manage 1999; 18:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/102\">",
"      Dodd MJ, Miaskowski C, Paul SM. Symptom clusters and their effect on the functional status of patients with cancer. Oncol Nurs Forum 2001; 28:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/103\">",
"      Romito F, Montanaro R, Corvasce C, et al. Is cancer-related fatigue more strongly correlated to haematological or to psychological factors in cancer patients? Support Care Cancer 2008; 16:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/104\">",
"      Goldstein D, Bennett B, Friedlander M, et al. Fatigue states after cancer treatment occur both in association with, and independent of, mood disorder: a longitudinal study. BMC Cancer 2006; 6:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/105\">",
"      Broeckel JA, Jacobsen PB, Horton J, et al. Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol 1998; 16:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/106\">",
"      Ahlberg K, Ekman T, Wallgren A, Gaston-Johansson F. Fatigue, psychological distress, coping and quality of life in patients with uterine cancer. J Adv Nurs 2004; 45:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/107\">",
"      Tchekmedyian NS, Kallich J, McDermott A, et al. The relationship between psychologic distress and cancer-related fatigue. Cancer 2003; 98:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/108\">",
"      Haghighat S, Akbari ME, Holakouei K, et al. Factors predicting fatigue in breast cancer patients. Support Care Cancer 2003; 11:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/109\">",
"      Hwang SS, Chang VT, Rue M, Kasimis B. Multidimensional independent predictors of cancer-related fatigue. J Pain Symptom Manage 2003; 26:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/110\">",
"      Jacobsen PB, Donovan KA, Weitzner MA. Distinguishing fatigue and depression in patients with cancer. Semin Clin Neuropsychiatry 2003; 8:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/111\">",
"      Passik SD, Dugan W, McDonald MV, et al. Oncologists' recognition of depression in their patients with cancer. J Clin Oncol 1998; 16:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/112\">",
"      Visser MR, Smets EM. Fatigue, depression and quality of life in cancer patients: how are they related? Support Care Cancer 1998; 6:101.",
"     </a>",
"    </li>",
"    <li>",
"     Morrow GR, Jean-Pierre P, Roscoe JA, et al. A phase III randomized, placebo-controlled, double-blind trial of a eugeroic agent in 642 cancer patients reporting fatigue during chemotherapy: a URCC CCOP study (abstract). J Clin Oncol 2008; 26:504s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/114\">",
"      Mystakidou K, Parpa E, Tsilika E, et al. The relationship of subjective sleep quality, pain, and quality of life in advanced cancer patients. Sleep 2007; 30:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/115\">",
"      Silberfarb PM, Hauri PJ, Oxman TE, Schnurr P. Assessment of sleep in patients with lung cancer and breast cancer. J Clin Oncol 1993; 11:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/116\">",
"      Savard J, Morin CM. Insomnia in the context of cancer: a review of a neglected problem. J Clin Oncol 2001; 19:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/117\">",
"      Savard J, Simard S, Blanchet J, et al. Prevalence, clinical characteristics, and risk factors for insomnia in the context of breast cancer. Sleep 2001; 24:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/118\">",
"      Savard J, Simard S, Hervouet S, et al. Insomnia in men treated with radical prostatectomy for prostate cancer. Psychooncology 2005; 14:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/119\">",
"      Savard J, Villa J, Ivers H, et al. Prevalence, natural course, and risk factors of insomnia comorbid with cancer over a 2-month period. J Clin Oncol 2009; 27:5233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/120\">",
"      Palesh OG, Roscoe JA, Mustian KM, et al. Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program. J Clin Oncol 2010; 28:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/62/11242/abstract/121\">",
"      Otte JL, Carpenter JS, Russell KM, et al. Prevalence, severity, and correlates of sleep-wake disturbances in long-term breast cancer survivors. J Pain Symptom Manage 2010; 39:535.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2802 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-115.124.72.62-5A3D10F1CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_62_11242=[""].join("\n");
var outline_f10_62_11242=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Time course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Chemotherapy and molecularly targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Biologic response modifiers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Androgen deprivation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Contribution of anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10233723\">",
"      Male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLINICAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Need for further evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Moderate to severe fatigue",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Assessment of disease status",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Treatable contributing factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Emotional disturbance/mood disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Sleep disturbance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Nutrition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Activity level",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2802\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2802|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/32/10763\" title=\"table 1\">",
"      NCI CTCAE grading scale for fatigue v4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/24/19852\" title=\"table 2\">",
"      Propose ICD10 crit CA fatigue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/4/7244\" title=\"table 3\">",
"      FACT fatigue anemia subscales",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/47/17149\" title=\"table 4\">",
"      Energy conservation methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/38/4715\" title=\"table 5\">",
"      Cancer related fatigue initial workup",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41496?source=related_link\">",
"      Acute side effects of adjuvant chemotherapy for early stage breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=related_link\">",
"      Bleomycin-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9290?source=related_link\">",
"      Cancer pain management with opioids: Prevention and management of side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27098?source=related_link\">",
"      Cancer-related fatigue: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=related_link\">",
"      Causes of secondary hypogonadism in males",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=related_link\">",
"      Clinical features and diagnosis of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17960?source=related_link\">",
"      Clinical features and pathogenesis of cancer cachexia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42362?source=related_link\">",
"      Enterotoxicity of chemotherapeutic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43719?source=related_link\">",
"      Functional problems in the patient with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23914?source=related_link\">",
"      Hematologic consequences of malignancy: Anemia and bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1447?source=related_link\">",
"      Ovarian failure due to anticancer drugs and radiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4758?source=related_link\">",
"      Overview of insomnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/4/29762?source=related_link\">",
"      Patient information: When your cancer treatment makes you tired (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5113?source=related_link\">",
"      Pharmacologic management of cancer anorexia/cachexia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=related_link\">",
"      Prevention and treatment of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=related_link\">",
"      Side effects of androgen deprivation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=related_link\">",
"      Sleep related breathing disorders in adults: Definitions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3690?source=related_link\">",
"      Various rehabilitation issues in patients treated for cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_62_11243="Prevention of GVHD with drugs";
var content_f10_62_11243=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F78611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F78611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Efficacy of drug prophylaxis for acute graft-versus-host disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug(s)",
"       </td>",
"       <td class=\"subtitle1\">",
"        GVHD, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        52-100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methotrexate",
"       </td>",
"       <td>",
"        56-70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclosporine",
"       </td>",
"       <td>",
"        33-54",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ATG-methotrexate-prednisone",
"       </td>",
"       <td>",
"        21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclosporine-methotrexate",
"       </td>",
"       <td>",
"        15-33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclosporine-prednisone",
"       </td>",
"       <td>",
"        12-21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclosporine-methotrexate-prednisone",
"       </td>",
"       <td>",
"        9-32",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     None of these regimens improve disease-free survival.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_62_11243=[""].join("\n");
var outline_f10_62_11243=null;
var title_f10_62_11244="Lumber mill antigens in HP";
var content_f10_62_11244=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hypersensitivity pneumonitides associated with milling and construction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Environmental source",
"       </td>",
"       <td class=\"subtitle1\">",
"        Major causative antigen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Wood dust pneumonitis (oak, cedar, and mahogany dust, pine and spruce pulp)",
"       </td>",
"       <td>",
"        Alternaria sp",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacillus subtilis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        Sequoiosis (moldy wood dust)",
"       </td>",
"       <td>",
"        Graphium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pullularia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trichoderma sp.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aureobasidium pullulans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maple bark disease (moldy maple bark)",
"       </td>",
"       <td>",
"        Cryptostroma corticale",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wood trimmer's disease (contaminated wood trimmings)",
"       </td>",
"       <td>",
"        Rhizopus sp, Mucor sp",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wood pulp worker's disease (oak and maple trees)",
"       </td>",
"       <td>",
"        Penicillium sp",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Suberosis (moldy cork dust)",
"       </td>",
"       <td>",
"        T. viridis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Penicillium glabrum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Conidia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Composter's lung",
"       </td>",
"       <td>",
"        T. vulgaris",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aspergillus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dry rot lung",
"       </td>",
"       <td>",
"        Merulius lacrymans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thatched-roof lung (huts in New Guinea)",
"       </td>",
"       <td>",
"        Saccharomonospora viridis (dead grasses and leaves)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Esparto dust (\"Stipatosis\"; Stipa tesnacissima is a grass of the graminea family)",
"       </td>",
"       <td>",
"        Aspergillus fumigatus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T. actinomycetes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_62_11244=[""].join("\n");
var outline_f10_62_11244=null;
var title_f10_62_11245="Acid production and excretion";
var content_f10_62_11245=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F71069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F71069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acid production and excretion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 322px; height: 251px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relationship between net renal acid excretion and endogenous acid production in the steady state in normal subjects ingesting different diets with varying acid content.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Kurtz, I, Kidney Int 1983; 24:670; and Lennon, EJ, J Clin Invest 1966; 45:1601.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_62_11245=[""].join("\n");
var outline_f10_62_11245=null;
var title_f10_62_11246="Hospitalization for neutropenia";
var content_f10_62_11246=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F81371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F81371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 493px\">",
"   <div class=\"ttl\">",
"    Hospitalization for neutropenia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 473px; height: 381px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Estimated hospitalization rates (per 10,000 days at risk) and 95 percent confidence intervals (vertical bars) for bacterial infection per absolute neutrophil count (ANC) stratum in 2047 HIV-infected patients. The values are based upon the earliest lowest ANC stratum for each patient. Hospitalization rates increased progressively when the ANC fell below 750/&micro;L.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Jacobson, MA, Liu, RC, Davies, D, Cohen, PT, Arch Intern Med 1997; 157:1825.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_62_11246=[""].join("\n");
var outline_f10_62_11246=null;
var title_f10_62_11247="Bleeding Mallory Weiss Endosc";
var content_f10_62_11247=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mallory-Weiss tear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 216px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopy shows an actively bleeding Mallory-Weiss tear at the gastroesophageal junction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Moises Guelrud, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_62_11247=[""].join("\n");
var outline_f10_62_11247=null;
  